[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fGbucIEvtVrbiuB31Q8hVr28UT_8nZ_DG7pDRuFxuexM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":82,"rows":89},"Jazz Pharmaceuticals",[4],200,false,20,71,29883,30,5,[14,17,19,21,24,27,30,32],{"name":15,"count":16},"Narcolepsy",14,{"name":18,"count":16},"Epilepsy",{"name":20,"count":16},"Pain",{"name":22,"count":23},"Multiple Sclerosis",13,{"name":25,"count":26},"Acute Myeloid Leukemia",10,{"name":28,"count":29},"Spasticity",6,{"name":31,"count":12},"Acute Lymphoblastic Leukemia",{"name":33,"count":12},"Fibromyalgia",[35,40,44,49,54,58,63,68,73,78],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04541082","Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms","2026-07","ONC206",{"nctId":41,"briefTitle":42,"date":38,"intervention":43},"NCT05772429","Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting","Epidiolex",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT07377539","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants","2026-07-05","JZP047",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05152147","A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","2026-07-31","Zanidatamab",{"nctId":55,"briefTitle":56,"date":57,"intervention":53},"NCT06695845","A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors","2026-12-31",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05485831","Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY","2027-02","Epidiolex 100 mg\u002FmL Oral Solution",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05044819","Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution","2027-08-01","Cannabidiol",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT07233239","A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures","2027-11-29","CBD-OS",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06108050","JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced\u002FMetastatic Solid Tumors","2027-11-30","JZP898",{"nctId":79,"briefTitle":80,"date":81,"intervention":53},"NCT07102381","A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer","2028-01-01",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,117,229,255,302,342,368,395,426,499,521,543,561,579,597,615,671,721,743,761,779,797,815,833,858,879,906,924,945,977,996,1164,1304,1354,1398,1420,1454,1472,1498,1516,1541,1616,1700,1772,1840,1892,1933,1978,2011,2033,2059,2093,2129,2155,2173,2191,2209,2232,2250,2268,2286,2311,2333,2359,2404,2452,2494,2527,2564,2586,2613,2643,2671,2697,2719,2737,2755,2773,2796,2814,2836,2861,2879,2904,2922,2949,2974,2992,3014,3032,3056,3078,3096,3114,3132,3150,3190,3226,3249,3267,3290,3313,3338,3356,3374,3397,3415,3433,3451,3474,3492,3515,3542,3560,3578,3680,3770,3848,3895,3938,3967,3991,4013,4037],{"intervention":67,"totalTrials":91,"cells":92},1,{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":115},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":95},[],{"trials":101,"activeCount":95},[],{"trials":103,"activeCount":91,"soonestReadout":66},[104],{"nctId":64,"briefTitle":65,"status":105,"phases":106,"primaryCompletion":66,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":114},"ACTIVE_NOT_RECRUITING",[87],"2028-03-31","2021-07-07",154,[111,112,113],"Lennox Gastaut Syndrome","Dravet Syndrome","Tuberous Sclerosis Complex",[67],{"trials":116,"activeCount":95},[],{"intervention":53,"totalTrials":118,"cells":119},7,{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":172,"PHASE4":217,"NA":219},{"trials":121,"activeCount":95},[],{"trials":123,"activeCount":95},[],{"trials":125,"activeCount":171,"soonestReadout":57},[126,141,158],{"nctId":79,"briefTitle":80,"status":127,"phases":128,"primaryCompletion":81,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":135},"RECRUITING",[85],"2030-08-01","2025-09-24",125,[133,134],"HER2-positive Breast Cancer","Breast Cancer",[53,136,137,138,139,140],"Paclitaxel","Docetaxel","Carboplatin","Trastuzumab","Pertuzumab",{"nctId":55,"briefTitle":56,"status":127,"phases":142,"primaryCompletion":57,"completion":143,"start":144,"enrollment":6,"conditions":145,"interventions":157},[85],"2027-12-31","2025-01-14",[134,146,147,148,149,150,151,152,153,154,155,156],"Gastric Cancer","Esophageal Cancer","Gastroesophageal Cancer","Colorectal Cancer","Endometrial Cancer","Non-small Cell Lung Cancer","Ovarian Cancer","Urothelial Carcinoma","Salivary Gland Cancer","Pancreatic Cancer","HER-2 Protein Overexpression",[53],{"nctId":159,"briefTitle":160,"status":161,"phases":162,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":169},"NCT05027139","A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer","COMPLETED",[84,85],"2025-07-07","2025-09-30","2021-09-15",52,[168],"HER2-expressing Cancers",[53,170],"Evorpacept",2,{"trials":173,"activeCount":216,"soonestReadout":52},[174,189,203],{"nctId":175,"briefTitle":176,"status":127,"phases":177,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":184},"NCT06435429","A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer",[86],"2028-04-28","2030-10-18","2024-08-13",550,[183],"Metastatic HER2-positive Breast Cancer",[53,139,185,186,187,188],"Eribulin","Vinorelbine","Gemcitabine","Capecitabine",{"nctId":190,"briefTitle":191,"status":127,"phases":192,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":199},"NCT06282575","Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer",[86],"2028-12-01","2030-04-01","2024-07-19",286,[198],"Biliary Tract Cancer",[53,200,187,201,202],"Cisplatin","Pembrolizumab","Durvalumab",{"nctId":50,"briefTitle":51,"status":105,"phases":204,"primaryCompletion":52,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":212},[86],"2027-07-31","2021-12-02",920,[209,210,211],"Gastric Neoplasms","Gastroesophageal Adenocarcinoma","Esophageal Adenocarcinoma",[53,213,139,188,214,200,215],"Tislelizumab","Oxaliplatin","5-Fluorouracil",3,{"trials":218,"activeCount":95},[],{"trials":220,"activeCount":95},[221],{"nctId":222,"briefTitle":223,"status":224,"phases":225,"conditions":226,"interventions":228},"NCT04578444","An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer","NO_LONGER_AVAILABLE",[],[227],"HER2-Positive Advanced Biliary Tract Cancer",[53],{"intervention":139,"totalTrials":216,"cells":230},{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":241,"PHASE4":251,"NA":253},{"trials":232,"activeCount":95},[],{"trials":234,"activeCount":95},[],{"trials":236,"activeCount":91,"soonestReadout":81},[237],{"nctId":79,"briefTitle":80,"status":127,"phases":238,"primaryCompletion":81,"completion":129,"start":130,"enrollment":131,"conditions":239,"interventions":240},[85],[133,134],[53,136,137,138,139,140],{"trials":242,"activeCount":171,"soonestReadout":52},[243,247],{"nctId":175,"briefTitle":176,"status":127,"phases":244,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":245,"interventions":246},[86],[183],[53,139,185,186,187,188],{"nctId":50,"briefTitle":51,"status":105,"phases":248,"primaryCompletion":52,"completion":205,"start":206,"enrollment":207,"conditions":249,"interventions":250},[86],[209,210,211],[53,213,139,188,214,200,215],{"trials":252,"activeCount":95},[],{"trials":254,"activeCount":95},[],{"intervention":188,"totalTrials":256,"cells":257},4,{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":273,"PHASE3":288,"PHASE4":298,"NA":300},{"trials":259,"activeCount":95},[],{"trials":261,"activeCount":95},[262],{"nctId":263,"briefTitle":264,"status":161,"phases":265,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":270},"NCT02892123","Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers",[84],"2024-10-31","2016-09-30",279,[168],[271,136,188,186,272,272],"ZW25","Tucatinib",{"trials":274,"activeCount":95},[275],{"nctId":276,"briefTitle":277,"status":161,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":284},"NCT03929666","A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",[85],"2025-08-30","2019-08-29",74,[283],"HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",[271,188,200,285,286,214,287,187],"Fluorouracil","Leucovorin","Bevacizumab",{"trials":289,"activeCount":171,"soonestReadout":52},[290,294],{"nctId":175,"briefTitle":176,"status":127,"phases":291,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":292,"interventions":293},[86],[183],[53,139,185,186,187,188],{"nctId":50,"briefTitle":51,"status":105,"phases":295,"primaryCompletion":52,"completion":205,"start":206,"enrollment":207,"conditions":296,"interventions":297},[86],[209,210,211],[53,213,139,188,214,200,215],{"trials":299,"activeCount":95},[],{"trials":301,"activeCount":95},[],{"intervention":187,"totalTrials":256,"cells":303},{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":328,"PHASE4":338,"NA":340},{"trials":305,"activeCount":95},[],{"trials":307,"activeCount":95},[],{"trials":309,"activeCount":95},[310,314],{"nctId":276,"briefTitle":277,"status":161,"phases":311,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":312,"interventions":313},[85],[283],[271,188,200,285,286,214,287,187],{"nctId":315,"briefTitle":316,"status":317,"phases":318,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":323,"interventions":325},"NCT01461915","Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients","TERMINATED",[85],"2012-12","2015-06","2011-11",60,[324],"Metastatic Pancreatic Cancer",[326,187,327],"Nab paclitaxel","Dociparstat",{"trials":329,"activeCount":171,"soonestReadout":178},[330,334],{"nctId":175,"briefTitle":176,"status":127,"phases":331,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":332,"interventions":333},[86],[183],[53,139,185,186,187,188],{"nctId":190,"briefTitle":191,"status":127,"phases":335,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":336,"interventions":337},[86],[198],[53,200,187,201,202],{"trials":339,"activeCount":95},[],{"trials":341,"activeCount":95},[],{"intervention":200,"totalTrials":216,"cells":343},{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":354,"PHASE4":364,"NA":366},{"trials":345,"activeCount":95},[],{"trials":347,"activeCount":95},[],{"trials":349,"activeCount":95},[350],{"nctId":276,"briefTitle":277,"status":161,"phases":351,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":352,"interventions":353},[85],[283],[271,188,200,285,286,214,287,187],{"trials":355,"activeCount":171,"soonestReadout":52},[356,360],{"nctId":190,"briefTitle":191,"status":127,"phases":357,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":358,"interventions":359},[86],[198],[53,200,187,201,202],{"nctId":50,"briefTitle":51,"status":105,"phases":361,"primaryCompletion":52,"completion":205,"start":206,"enrollment":207,"conditions":362,"interventions":363},[86],[209,210,211],[53,213,139,188,214,200,215],{"trials":365,"activeCount":95},[],{"trials":367,"activeCount":95},[],{"intervention":201,"totalTrials":171,"cells":369},{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":383,"PHASE3":385,"PHASE4":391,"NA":393},{"trials":371,"activeCount":95},[],{"trials":373,"activeCount":91,"soonestReadout":76},[374],{"nctId":74,"briefTitle":75,"status":127,"phases":375,"primaryCompletion":76,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":382},[84],"2028-05-31","2023-11-07",177,[380,381],"Advanced Solid Tumor","Metastatic Solid Tumor",[77,201],{"trials":384,"activeCount":95},[],{"trials":386,"activeCount":91,"soonestReadout":193},[387],{"nctId":190,"briefTitle":191,"status":127,"phases":388,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":389,"interventions":390},[86],[198],[53,200,187,201,202],{"trials":392,"activeCount":95},[],{"trials":394,"activeCount":95},[],{"intervention":202,"totalTrials":171,"cells":396},{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":416,"PHASE4":422,"NA":424},{"trials":398,"activeCount":95},[],{"trials":400,"activeCount":95},[],{"trials":402,"activeCount":91,"soonestReadout":408},[403],{"nctId":404,"briefTitle":405,"status":406,"phases":407,"primaryCompletion":408,"completion":409,"start":410,"enrollment":411,"conditions":412,"interventions":414},"NCT07459634","A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC","NOT_YET_RECRUITING",[85],"2028-01-31","2028-04-30","2026-06-12",50,[413],"Extensive-stage Small-cell Lung Cancer",[415,202],"Lurbinectedin",{"trials":417,"activeCount":91,"soonestReadout":193},[418],{"nctId":190,"briefTitle":191,"status":127,"phases":419,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":420,"interventions":421},[86],[198],[53,200,187,201,202],{"trials":423,"activeCount":95},[],{"trials":425,"activeCount":95},[],{"intervention":427,"totalTrials":12,"cells":428},"Dordaviprone",{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":445,"PHASE3":482,"PHASE4":495,"NA":497},{"trials":430,"activeCount":95},[],{"trials":432,"activeCount":95},[433],{"nctId":434,"briefTitle":435,"status":317,"phases":436,"primaryCompletion":437,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":444},"NCT03416530","ONC201 in Pediatric H3 K27M Gliomas",[84],"2022-12-31","2023-05-24","2018-01-25",134,[442,443],"Diffuse Intrinsic Pontine Glioma","Glioma, Malignant",[427],{"trials":446,"activeCount":95},[447,457,472],{"nctId":448,"briefTitle":449,"status":317,"phases":450,"primaryCompletion":437,"completion":451,"start":452,"enrollment":453,"conditions":454,"interventions":456},"NCT03295396","ONC201 in Adults With Recurrent H3 K27M-mutant Glioma",[85],"2023-07-19","2017-10-30",73,[455],"Glioma",[427],{"nctId":458,"briefTitle":459,"status":317,"phases":460,"primaryCompletion":461,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":471},"NCT02525692","Oral ONC201 in Adult Recurrent Glioblastoma",[85],"2023-04-17","2016-01",84,[465,466,467,468,469,470],"Glioblastoma","Diffuse Midline Glioma","H3 K27M Glioma","Thalamic Glioma","Infratentorial Glioma","Basal Ganglia Glioma",[427],{"nctId":473,"briefTitle":474,"status":317,"phases":475,"primaryCompletion":476,"completion":476,"start":477,"enrollment":478,"conditions":479,"interventions":481},"NCT03485729","ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer",[85],"2023-01-19","2018-03-21",27,[480],"Endometrial Cancer Recurrent",[427],{"trials":483,"activeCount":91,"soonestReadout":488},[484],{"nctId":485,"briefTitle":486,"status":127,"phases":487,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":493},"NCT05580562","ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)",[86],"2028-06","2023-01-23",510,[492,455],"H3 K27M",[427,494],"Dordaviprone (ONC201) + Placebo",{"trials":496,"activeCount":95},[],{"trials":498,"activeCount":95},[],{"intervention":214,"totalTrials":171,"cells":500},{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":511,"PHASE4":517,"NA":519},{"trials":502,"activeCount":95},[],{"trials":504,"activeCount":95},[],{"trials":506,"activeCount":95},[507],{"nctId":276,"briefTitle":277,"status":161,"phases":508,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":509,"interventions":510},[85],[283],[271,188,200,285,286,214,287,187],{"trials":512,"activeCount":91,"soonestReadout":52},[513],{"nctId":50,"briefTitle":51,"status":105,"phases":514,"primaryCompletion":52,"completion":205,"start":206,"enrollment":207,"conditions":515,"interventions":516},[86],[209,210,211],[53,213,139,188,214,200,215],{"trials":518,"activeCount":95},[],{"trials":520,"activeCount":95},[],{"intervention":186,"totalTrials":171,"cells":522},{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":531,"PHASE3":533,"PHASE4":539,"NA":541},{"trials":524,"activeCount":95},[],{"trials":526,"activeCount":95},[527],{"nctId":263,"briefTitle":264,"status":161,"phases":528,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":529,"interventions":530},[84],[168],[271,136,188,186,272,272],{"trials":532,"activeCount":95},[],{"trials":534,"activeCount":91,"soonestReadout":178},[535],{"nctId":175,"briefTitle":176,"status":127,"phases":536,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":537,"interventions":538},[86],[183],[53,139,185,186,187,188],{"trials":540,"activeCount":95},[],{"trials":542,"activeCount":95},[],{"intervention":494,"totalTrials":91,"cells":544},{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":551,"PHASE4":557,"NA":559},{"trials":546,"activeCount":95},[],{"trials":548,"activeCount":95},[],{"trials":550,"activeCount":95},[],{"trials":552,"activeCount":91,"soonestReadout":488},[553],{"nctId":485,"briefTitle":486,"status":127,"phases":554,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":555,"interventions":556},[86],[492,455],[427,494],{"trials":558,"activeCount":95},[],{"trials":560,"activeCount":95},[],{"intervention":185,"totalTrials":91,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":569,"PHASE4":575,"NA":577},{"trials":564,"activeCount":95},[],{"trials":566,"activeCount":95},[],{"trials":568,"activeCount":95},[],{"trials":570,"activeCount":91,"soonestReadout":178},[571],{"nctId":175,"briefTitle":176,"status":127,"phases":572,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":573,"interventions":574},[86],[183],[53,139,185,186,187,188],{"trials":576,"activeCount":95},[],{"trials":578,"activeCount":95},[],{"intervention":213,"totalTrials":91,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":593,"NA":595},{"trials":582,"activeCount":95},[],{"trials":584,"activeCount":95},[],{"trials":586,"activeCount":95},[],{"trials":588,"activeCount":91,"soonestReadout":52},[589],{"nctId":50,"briefTitle":51,"status":105,"phases":590,"primaryCompletion":52,"completion":205,"start":206,"enrollment":207,"conditions":591,"interventions":592},[86],[209,210,211],[53,213,139,188,214,200,215],{"trials":594,"activeCount":95},[],{"trials":596,"activeCount":95},[],{"intervention":215,"totalTrials":91,"cells":598},{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":611,"NA":613},{"trials":600,"activeCount":95},[],{"trials":602,"activeCount":95},[],{"trials":604,"activeCount":95},[],{"trials":606,"activeCount":91,"soonestReadout":52},[607],{"nctId":50,"briefTitle":51,"status":105,"phases":608,"primaryCompletion":52,"completion":205,"start":206,"enrollment":207,"conditions":609,"interventions":610},[86],[209,210,211],[53,213,139,188,214,200,215],{"trials":612,"activeCount":95},[],{"trials":614,"activeCount":95},[],{"intervention":39,"totalTrials":171,"cells":616},{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":650,"PHASE3":665,"PHASE4":667,"NA":669},{"trials":618,"activeCount":95},[],{"trials":620,"activeCount":91,"soonestReadout":38},[621],{"nctId":36,"briefTitle":37,"status":127,"phases":622,"primaryCompletion":38,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":649},[84],"2026-12","2020-10-26",102,[627,465,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648],"Central Nervous System Neoplasms","Gliosarcoma, Adult","Anaplastic Oligodendroglioma","Anaplastic Astrocytoma","Pilocytic Astrocytoma","Oligodendroglioma","Gliomatosis Cerebri","Pleomorphic Xanthoastrocytoma","Anaplastic Pleomorphic Xanthoastrocytoma","Diffuse Midline Glioma, H3 K27M-Mutant","Ependymoma","Ependymoma, Anaplastic","Medulloblastoma","Teratoid Rhabdoid Tumor","Neuroectodermal Tumors, Primitive","Neuroectodermal Tumors","Anaplastic Meningioma","Atypical Meningioma","Choroid Plexus Neoplasms","Pineal Tumor","Diffuse Astrocytoma","Glial Tumor",[39],{"trials":651,"activeCount":91,"soonestReadout":656},[652],{"nctId":653,"briefTitle":654,"status":127,"phases":655,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":659,"interventions":662},"NCT07282587","Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma",[85],"2028-12-15","2026-01-02",90,[660,661],"Advanced Pheochromocytoma and Paraganglioma","PCPG",[39,663,664],"ONC206: Dose 1","ONC206: Dose 2",{"trials":666,"activeCount":95},[],{"trials":668,"activeCount":95},[],{"trials":670,"activeCount":95},[],{"intervention":415,"totalTrials":256,"cells":672},{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":677,"PHASE3":707,"PHASE4":709,"NA":711},{"trials":674,"activeCount":95},[],{"trials":676,"activeCount":95},[],{"trials":678,"activeCount":171,"soonestReadout":683},[679,691,703],{"nctId":680,"briefTitle":681,"status":127,"phases":682,"primaryCompletion":683,"completion":684,"start":685,"enrollment":322,"conditions":686,"interventions":690},"NCT05734066","Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed\u002FRefractory Ewing Sarcoma",[84,85],"2028-01-28","2028-04-20","2023-05-23",[687,688,689],"Refractory Ewing Sarcoma","Relapsed Ewing Sarcoma","Ewing Sarcoma",[415],{"nctId":692,"briefTitle":693,"status":317,"phases":694,"primaryCompletion":695,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":702},"NCT05126433","Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors",[85],"2023-12-20","2022-03-03",47,[380,381,699,700,701],"Urothelial Cancer","Poorly Differentiated Neuroendocrine Carcinomas","Homologous Recombination Deficient-Positive Malignancies Agnostic",[415],{"nctId":404,"briefTitle":405,"status":406,"phases":704,"primaryCompletion":408,"completion":409,"start":410,"enrollment":411,"conditions":705,"interventions":706},[85],[413],[415,202],{"trials":708,"activeCount":95},[],{"trials":710,"activeCount":95},[],{"trials":712,"activeCount":95},[713],{"nctId":714,"briefTitle":715,"status":716,"phases":717,"conditions":718,"interventions":720},"NCT04291937","A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA","APPROVED_FOR_MARKETING",[],[719],"Small Cell Lung Cancer",[415],{"intervention":136,"totalTrials":171,"cells":722},{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":731,"PHASE3":737,"PHASE4":739,"NA":741},{"trials":724,"activeCount":95},[],{"trials":726,"activeCount":95},[727],{"nctId":263,"briefTitle":264,"status":161,"phases":728,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":729,"interventions":730},[84],[168],[271,136,188,186,272,272],{"trials":732,"activeCount":91,"soonestReadout":81},[733],{"nctId":79,"briefTitle":80,"status":127,"phases":734,"primaryCompletion":81,"completion":129,"start":130,"enrollment":131,"conditions":735,"interventions":736},[85],[133,134],[53,136,137,138,139,140],{"trials":738,"activeCount":95},[],{"trials":740,"activeCount":95},[],{"trials":742,"activeCount":95},[],{"intervention":137,"totalTrials":91,"cells":744},{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":755,"PHASE4":757,"NA":759},{"trials":746,"activeCount":95},[],{"trials":748,"activeCount":95},[],{"trials":750,"activeCount":91,"soonestReadout":81},[751],{"nctId":79,"briefTitle":80,"status":127,"phases":752,"primaryCompletion":81,"completion":129,"start":130,"enrollment":131,"conditions":753,"interventions":754},[85],[133,134],[53,136,137,138,139,140],{"trials":756,"activeCount":95},[],{"trials":758,"activeCount":95},[],{"trials":760,"activeCount":95},[],{"intervention":138,"totalTrials":91,"cells":762},{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":773,"PHASE4":775,"NA":777},{"trials":764,"activeCount":95},[],{"trials":766,"activeCount":95},[],{"trials":768,"activeCount":91,"soonestReadout":81},[769],{"nctId":79,"briefTitle":80,"status":127,"phases":770,"primaryCompletion":81,"completion":129,"start":130,"enrollment":131,"conditions":771,"interventions":772},[85],[133,134],[53,136,137,138,139,140],{"trials":774,"activeCount":95},[],{"trials":776,"activeCount":95},[],{"trials":778,"activeCount":95},[],{"intervention":140,"totalTrials":91,"cells":780},{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":791,"PHASE4":793,"NA":795},{"trials":782,"activeCount":95},[],{"trials":784,"activeCount":95},[],{"trials":786,"activeCount":91,"soonestReadout":81},[787],{"nctId":79,"briefTitle":80,"status":127,"phases":788,"primaryCompletion":81,"completion":129,"start":130,"enrollment":131,"conditions":789,"interventions":790},[85],[133,134],[53,136,137,138,139,140],{"trials":792,"activeCount":95},[],{"trials":794,"activeCount":95},[],{"trials":796,"activeCount":95},[],{"intervention":663,"totalTrials":91,"cells":798},{"EARLY_PHASE1":799,"PHASE1":801,"PHASE2":803,"PHASE3":809,"PHASE4":811,"NA":813},{"trials":800,"activeCount":95},[],{"trials":802,"activeCount":95},[],{"trials":804,"activeCount":91,"soonestReadout":656},[805],{"nctId":653,"briefTitle":654,"status":127,"phases":806,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":807,"interventions":808},[85],[660,661],[39,663,664],{"trials":810,"activeCount":95},[],{"trials":812,"activeCount":95},[],{"trials":814,"activeCount":95},[],{"intervention":664,"totalTrials":91,"cells":816},{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":827,"PHASE4":829,"NA":831},{"trials":818,"activeCount":95},[],{"trials":820,"activeCount":95},[],{"trials":822,"activeCount":91,"soonestReadout":656},[823],{"nctId":653,"briefTitle":654,"status":127,"phases":824,"primaryCompletion":656,"completion":656,"start":657,"enrollment":658,"conditions":825,"interventions":826},[85],[660,661],[39,663,664],{"trials":828,"activeCount":95},[],{"trials":830,"activeCount":95},[],{"trials":832,"activeCount":95},[],{"intervention":834,"totalTrials":91,"cells":835},"JZP3507",{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":837,"activeCount":95},[],{"trials":839,"activeCount":95},[],{"trials":841,"activeCount":91,"soonestReadout":846},[842],{"nctId":843,"briefTitle":844,"status":406,"phases":845,"primaryCompletion":846,"completion":847,"start":848,"enrollment":11,"conditions":849,"interventions":851},"NCT07533942","A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma",[85],"2028-10-25","2031-10-16","2026-06-01",[850],"Meningioma",[834],{"trials":853,"activeCount":95},[],{"trials":855,"activeCount":95},[],{"trials":857,"activeCount":95},[],{"intervention":72,"totalTrials":91,"cells":859},{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":871,"PHASE3":873,"PHASE4":875,"NA":877},{"trials":861,"activeCount":95},[],{"trials":863,"activeCount":91,"soonestReadout":71},[864],{"nctId":69,"briefTitle":70,"status":127,"phases":865,"primaryCompletion":71,"completion":71,"start":866,"enrollment":867,"conditions":868,"interventions":870},[84],"2025-11-26",100,[869],"Focal Seizures",[72],{"trials":872,"activeCount":95},[],{"trials":874,"activeCount":95},[],{"trials":876,"activeCount":95},[],{"trials":878,"activeCount":95},[],{"intervention":880,"totalTrials":91,"cells":881},"JZP815",{"EARLY_PHASE1":882,"PHASE1":884,"PHASE2":898,"PHASE3":900,"PHASE4":902,"NA":904},{"trials":883,"activeCount":95},[],{"trials":885,"activeCount":91,"soonestReadout":890},[886],{"nctId":887,"briefTitle":888,"status":127,"phases":889,"primaryCompletion":890,"completion":890,"start":891,"enrollment":892,"conditions":893,"interventions":897},"NCT05557045","A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815",[84],"2028-04-01","2022-10-10",332,[894,895,896],"Advanced Cancer","Metastatic Cancer","Solid Tumor",[880],{"trials":899,"activeCount":95},[],{"trials":901,"activeCount":95},[],{"trials":903,"activeCount":95},[],{"trials":905,"activeCount":95},[],{"intervention":77,"totalTrials":91,"cells":907},{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":916,"PHASE3":918,"PHASE4":920,"NA":922},{"trials":909,"activeCount":95},[],{"trials":911,"activeCount":91,"soonestReadout":76},[912],{"nctId":74,"briefTitle":75,"status":127,"phases":913,"primaryCompletion":76,"completion":376,"start":377,"enrollment":378,"conditions":914,"interventions":915},[84],[380,381],[77,201],{"trials":917,"activeCount":95},[],{"trials":919,"activeCount":95},[],{"trials":921,"activeCount":95},[],{"trials":923,"activeCount":95},[],{"intervention":48,"totalTrials":91,"cells":925},{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":937,"PHASE3":939,"PHASE4":941,"NA":943},{"trials":927,"activeCount":95},[],{"trials":929,"activeCount":91,"soonestReadout":47},[930],{"nctId":45,"briefTitle":46,"status":127,"phases":931,"primaryCompletion":47,"completion":47,"start":932,"enrollment":933,"conditions":934,"interventions":936},[84],"2026-02-03",86,[935],"Healthy Participants",[48],{"trials":938,"activeCount":95},[],{"trials":940,"activeCount":95},[],{"trials":942,"activeCount":95},[],{"trials":944,"activeCount":95},[],{"intervention":43,"totalTrials":171,"cells":946},{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":951,"PHASE3":953,"PHASE4":955,"NA":957},{"trials":948,"activeCount":95},[],{"trials":950,"activeCount":95},[],{"trials":952,"activeCount":95},[],{"trials":954,"activeCount":95},[],{"trials":956,"activeCount":95},[],{"trials":958,"activeCount":171,"soonestReadout":38},[959,971],{"nctId":960,"briefTitle":961,"status":127,"phases":962,"primaryCompletion":963,"completion":963,"start":964,"enrollment":411,"conditions":965,"interventions":970},"NCT06113237","Pregnancy Surveillance Program of Patients Exposed to Epidiolex\u002FEpidyolex During Pregnancy",[],"2033-08-31","2025-08-05",[966,967,968,969],"Maternal Complications","Pregnancy Complication","Birth Outcomes, Adverse","Pregnancy",[43],{"nctId":41,"briefTitle":42,"status":105,"phases":972,"primaryCompletion":38,"completion":38,"start":461,"enrollment":973,"conditions":974,"interventions":976},[],158,[975],"Seizures",[43],{"intervention":62,"totalTrials":91,"cells":978},{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":985,"PHASE4":987,"NA":989},{"trials":980,"activeCount":95},[],{"trials":982,"activeCount":95},[],{"trials":984,"activeCount":95},[],{"trials":986,"activeCount":95},[],{"trials":988,"activeCount":95},[],{"trials":990,"activeCount":91,"soonestReadout":61},[991],{"nctId":59,"briefTitle":60,"status":127,"phases":992,"primaryCompletion":61,"completion":61,"start":993,"enrollment":867,"conditions":994,"interventions":995},[],"2025-02-24",[111,112,113],[62],{"intervention":997,"totalTrials":998,"cells":999},"GWP42003-P",16,{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1054,"PHASE4":1150,"NA":1162},{"trials":1001,"activeCount":95},[],{"trials":1003,"activeCount":95},[],{"trials":1005,"activeCount":95},[1006,1016,1026,1036,1046],{"nctId":1007,"briefTitle":1008,"status":317,"phases":1009,"primaryCompletion":1010,"completion":1010,"start":1011,"enrollment":1012,"conditions":1013,"interventions":1015},"NCT04421456","Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment",[85],"2022-03-16","2020-08-18",95,[1014],"Schizophrenia",[997],{"nctId":1017,"briefTitle":1018,"status":161,"phases":1019,"primaryCompletion":1020,"completion":1021,"start":1022,"enrollment":1023,"conditions":1024,"interventions":1025},"NCT02607891","A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy",[85],"2018-09-11","2018-10-02","2016-11-09",35,[18],[997],{"nctId":1027,"briefTitle":1028,"status":161,"phases":1029,"primaryCompletion":1030,"completion":1030,"start":1031,"enrollment":1032,"conditions":1033,"interventions":1034},"NCT02564952","An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol",[85],"2017-06-07","2016-03-11",18,[18],[997,1035],"Clobazam",{"nctId":1037,"briefTitle":1038,"status":161,"phases":1039,"primaryCompletion":1040,"completion":1040,"start":1041,"enrollment":1042,"conditions":1043,"interventions":1045},"NCT04745026","Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder",[85],"2023-12-21","2021-05-31",103,[1044],"Autism Spectrum Disorder",[997],{"nctId":1047,"briefTitle":1048,"status":161,"phases":1049,"primaryCompletion":1050,"completion":1050,"start":1051,"enrollment":11,"conditions":1052,"interventions":1053},"NCT02607904","An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy",[85],"2019-05-27","2016-12-15",[18],[997],{"trials":1055,"activeCount":95},[1056,1066,1075,1086,1097,1106,1116,1124,1132,1141],{"nctId":1057,"briefTitle":1058,"status":161,"phases":1059,"primaryCompletion":1060,"completion":1061,"start":1062,"enrollment":1063,"conditions":1064,"interventions":1065},"NCT02544763","A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)",[86],"2019-01-22","2019-02-26","2016-04-06",224,[113,975],[997],{"nctId":1067,"briefTitle":1068,"status":161,"phases":1069,"primaryCompletion":1070,"completion":1070,"start":1071,"enrollment":1072,"conditions":1073,"interventions":1074},"NCT02224560","Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults",[86],"2016-05-19","2015-06-08",225,[18,111],[997],{"nctId":1076,"briefTitle":1077,"status":317,"phases":1078,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":1082,"interventions":1085},"NCT04252586","A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome",[86],"2021-06-09","2020-02-28",21,[1083,1084],"Rett Syndrome","RTT",[997],{"nctId":1087,"briefTitle":1088,"status":317,"phases":1089,"primaryCompletion":1090,"completion":1090,"start":1091,"enrollment":216,"conditions":1092,"interventions":1096},"NCT04485104","Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures",[86],"2025-01-28","2021-05-19",[1093,1094,1095],"Seizure in Participants With Tuberous Sclerosis Complex","Seizure in Participants With Dravet Syndrome","Seizure in Participants With Lennox-Gastaut Syndrome",[997],{"nctId":1098,"briefTitle":1099,"status":161,"phases":1100,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":1104,"interventions":1105},"NCT02544750","An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)",[86],"2021-06-11","2016-08-31",199,[113,975],[997],{"nctId":1107,"briefTitle":1108,"status":161,"phases":1109,"primaryCompletion":1110,"completion":1110,"start":1111,"enrollment":1112,"conditions":1113,"interventions":1115},"NCT02953548","Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)",[86],"2018-05-07","2017-04-24",9,[1114],"Infantile Spasms",[997],{"nctId":1117,"briefTitle":1118,"status":161,"phases":1119,"primaryCompletion":1120,"completion":1120,"start":1121,"enrollment":1103,"conditions":1122,"interventions":1123},"NCT02224703","GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome",[86],"2018-04-09","2015-04-13",[18,112],[997],{"nctId":1125,"briefTitle":1126,"status":161,"phases":1127,"primaryCompletion":1128,"completion":1128,"start":1129,"enrollment":1112,"conditions":1130,"interventions":1131},"NCT02954887","Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)",[86],"2019-06-13","2017-05-12",[1114],[997],{"nctId":1133,"briefTitle":1134,"status":317,"phases":1135,"primaryCompletion":1136,"completion":1136,"start":1137,"enrollment":216,"conditions":1138,"interventions":1140},"NCT05288283","Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures",[86],"2023-09-28","2022-10-31",[1139],"Seizures Associated With EMAS",[997],{"nctId":1142,"briefTitle":1143,"status":317,"phases":1144,"primaryCompletion":1145,"completion":1145,"start":1146,"enrollment":1147,"conditions":1148,"interventions":1149},"NCT03848832","Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome",[86],"2021-01-21","2019-07-29",29,[1083,1084],[997],{"trials":1151,"activeCount":95},[1152],{"nctId":1153,"briefTitle":1154,"status":1155,"phases":1156,"primaryCompletion":1157,"completion":1157,"start":1158,"enrollment":95,"conditions":1159,"interventions":1161},"NCT04133480","Investigation of Cognitive Outcomes With Cannabidiol Oral Solution","WITHDRAWN",[87],"2021-12","2020-10",[1160],"Lennox-Gastaut Syndrome",[997],{"trials":1163,"activeCount":95},[],{"intervention":1165,"totalTrials":23,"cells":1166},"Sativex",{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1201,"PHASE3":1220,"PHASE4":1291,"NA":1302},{"trials":1168,"activeCount":95},[],{"trials":1170,"activeCount":95},[1171,1182,1191],{"nctId":1172,"briefTitle":1173,"status":161,"phases":1174,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1180},"NCT01323569","Abuse Potential of Sativex",[84],"2008-06","2008-02",58,[1179],"Evaluation of Abuse Potential of Sativex",[1165,1165,1165,1181,1181],"Marinol",{"nctId":1183,"briefTitle":1184,"status":161,"phases":1185,"primaryCompletion":1176,"completion":1176,"start":1186,"enrollment":1187,"conditions":1188,"interventions":1190},"NCT01322464","Study to Assess Food Effect on Sativex Bioavailability",[84],"2008-01",25,[1189],"Food Effect",[1165,1165,1165,1165],{"nctId":1192,"briefTitle":1193,"status":161,"phases":1194,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":1197,"conditions":1198,"interventions":1200},"NCT01887301","Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients",[84],"2014-05","2013-07",32,[1199],"Hepatic Impairment",[1165],{"trials":1202,"activeCount":95},[1203,1213],{"nctId":1204,"briefTitle":1205,"status":161,"phases":1206,"primaryCompletion":1207,"completion":1208,"start":1209,"enrollment":29,"conditions":1210,"interventions":1212},"NCT01812603","A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma",[84,85],"2015-01","2016-06","2013-09",[1211],"Cancer",[1165],{"nctId":1214,"briefTitle":1215,"status":161,"phases":1216,"primaryCompletion":1208,"completion":1208,"start":1217,"enrollment":1081,"conditions":1218,"interventions":1219},"NCT01812616","A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients",[84,85],"2014-09",[1211],[1165],{"trials":1221,"activeCount":95},[1222,1232,1241,1251,1260,1270,1280],{"nctId":1223,"briefTitle":1224,"status":161,"phases":1225,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":1228,"conditions":1229,"interventions":1230},"NCT00675948","Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain",[86],"2006-09","2002-04",43,[20,1211],[1165,1231],"GW-2000-02",{"nctId":1233,"briefTitle":1234,"status":161,"phases":1235,"primaryCompletion":1236,"completion":1236,"start":1237,"enrollment":1238,"conditions":1239,"interventions":1240},"NCT00702468","Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis",[86],"2009-01","2007-11",36,[28,22],[1165],{"nctId":1242,"briefTitle":1243,"status":161,"phases":1244,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":1247,"conditions":1248,"interventions":1250},"NCT00710424","A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy",[86],"2006-06","2005-07",297,[20,1249],"Diabetic Neuropathy",[1165],{"nctId":1252,"briefTitle":1253,"status":161,"phases":1254,"primaryCompletion":1255,"completion":1255,"start":1256,"enrollment":1257,"conditions":1258,"interventions":1259},"NCT01599234","A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis",[86],"2005-12","2005-03",337,[22],[1165],{"nctId":1261,"briefTitle":1262,"status":161,"phases":1263,"primaryCompletion":1264,"completion":1264,"start":1265,"enrollment":1266,"conditions":1267,"interventions":1269},"NCT01604265","A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis",[86],"2002-08","2002-03",66,[22,1268],"Neuropathic Pain",[1165],{"nctId":1271,"briefTitle":1272,"status":161,"phases":1273,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1276,"conditions":1277,"interventions":1279},"NCT00710554","A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia",[86],"2006-10","2005-08",246,[20,1278],"Peripheral Neuropathy",[1165],{"nctId":1281,"briefTitle":1282,"status":161,"phases":1283,"primaryCompletion":1284,"completion":1285,"start":1286,"enrollment":1287,"conditions":1288,"interventions":1290},"NCT01898520","A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years",[86],"2016-09","2017-03","2013-12",72,[1289],"Cerebral Palsy",[1165],{"trials":1292,"activeCount":95},[1293],{"nctId":1294,"briefTitle":1295,"status":161,"phases":1296,"primaryCompletion":1297,"completion":1297,"start":1298,"enrollment":1299,"conditions":1300,"interventions":1301},"NCT01964547","A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients",[87],"2013-05","2012-01",121,[22,28],[1165],{"trials":1303,"activeCount":95},[],{"intervention":1305,"totalTrials":216,"cells":1306},"Xyrem",{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1313,"PHASE4":1339,"NA":1352},{"trials":1308,"activeCount":95},[],{"trials":1310,"activeCount":95},[],{"trials":1312,"activeCount":95},[],{"trials":1314,"activeCount":95},[1315,1328],{"nctId":1316,"briefTitle":1317,"status":161,"phases":1318,"primaryCompletion":1319,"completion":1320,"start":1321,"enrollment":1322,"conditions":1323,"interventions":1324},"NCT00066170","Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy",[86],"2004-07","2004-11","2003-04",231,[15],[1305,1325,1326,1327],"Xyrem Placebo","Modafinil at established dose","Modafinil",{"nctId":1329,"briefTitle":1330,"status":161,"phases":1331,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":1335,"conditions":1336,"interventions":1338},"NCT02221869","A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy",[86],"2017-02","2019-01-25","2014-10-01",106,[1337],"Narcolepsy With Cataplexy",[1305],{"trials":1340,"activeCount":95},[1341],{"nctId":1342,"briefTitle":1343,"status":161,"phases":1344,"primaryCompletion":1345,"completion":1346,"start":1347,"enrollment":322,"conditions":1348,"interventions":1350},"NCT00086281","Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients",[87],"2005-06","2005-11","2003-11",[1349],"Obstructive Sleep Apnea Syndrome",[1305,1351,1327],"Zolpidem",{"trials":1353,"activeCount":95},[],{"intervention":1355,"totalTrials":216,"cells":1356},"JZP-258",{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1363,"PHASE4":1385,"NA":1396},{"trials":1358,"activeCount":95},[],{"trials":1360,"activeCount":95},[],{"trials":1362,"activeCount":95},[],{"trials":1364,"activeCount":95},[1365,1375],{"nctId":1366,"briefTitle":1367,"status":161,"phases":1368,"primaryCompletion":1369,"completion":1370,"start":1371,"enrollment":1372,"conditions":1373,"interventions":1374},"NCT03030599","A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy",[86],"2019-01-24","2019-07-10","2017-03-14",201,[1337],[1355],{"nctId":1376,"briefTitle":1377,"status":161,"phases":1378,"primaryCompletion":1379,"completion":1380,"start":1381,"enrollment":109,"conditions":1382,"interventions":1384},"NCT03533114","A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension",[86],"2020-06-12","2020-12-18","2018-11-27",[1383],"Idiopathic Hypersomnia",[1355],{"trials":1386,"activeCount":95},[1387],{"nctId":1388,"briefTitle":1389,"status":161,"phases":1390,"primaryCompletion":1391,"completion":1391,"start":1392,"enrollment":1393,"conditions":1394,"interventions":1395},"NCT04794491","An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy",[87],"2022-11-15","2021-03-22",62,[15],[1355],{"trials":1397,"activeCount":95},[],{"intervention":1327,"totalTrials":171,"cells":1399},{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1404,"PHASE3":1406,"PHASE4":1412,"NA":1418},{"trials":1401,"activeCount":95},[],{"trials":1403,"activeCount":95},[],{"trials":1405,"activeCount":95},[],{"trials":1407,"activeCount":95},[1408],{"nctId":1316,"briefTitle":1317,"status":161,"phases":1409,"primaryCompletion":1319,"completion":1320,"start":1321,"enrollment":1322,"conditions":1410,"interventions":1411},[86],[15],[1305,1325,1326,1327],{"trials":1413,"activeCount":95},[1414],{"nctId":1342,"briefTitle":1343,"status":161,"phases":1415,"primaryCompletion":1345,"completion":1346,"start":1347,"enrollment":322,"conditions":1416,"interventions":1417},[87],[1349],[1305,1351,1327],{"trials":1419,"activeCount":95},[],{"intervention":1421,"totalTrials":171,"cells":1422},"JZP258",{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1429,"PHASE4":1431,"NA":1452},{"trials":1424,"activeCount":95},[],{"trials":1426,"activeCount":95},[],{"trials":1428,"activeCount":95},[],{"trials":1430,"activeCount":95},[],{"trials":1432,"activeCount":95},[1433,1442],{"nctId":1434,"briefTitle":1435,"status":161,"phases":1436,"primaryCompletion":1437,"completion":1437,"start":1438,"enrollment":1439,"conditions":1440,"interventions":1441},"NCT05875974","A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy",[87],"2025-03-13","2023-07-27",207,[1383,15],[1421],{"nctId":1443,"briefTitle":1444,"status":161,"phases":1445,"primaryCompletion":1446,"completion":1447,"start":1448,"enrollment":1449,"conditions":1450,"interventions":1451},"NCT05869773","A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy",[87],"2025-02-25","2025-03-10","2023-06-26",155,[15],[1421],{"trials":1453,"activeCount":95},[],{"intervention":1351,"totalTrials":91,"cells":1455},{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1460,"PHASE3":1462,"PHASE4":1464,"NA":1470},{"trials":1457,"activeCount":95},[],{"trials":1459,"activeCount":95},[],{"trials":1461,"activeCount":95},[],{"trials":1463,"activeCount":95},[],{"trials":1465,"activeCount":95},[1466],{"nctId":1342,"briefTitle":1343,"status":161,"phases":1467,"primaryCompletion":1345,"completion":1346,"start":1347,"enrollment":322,"conditions":1468,"interventions":1469},[87],[1349],[1305,1351,1327],{"trials":1471,"activeCount":95},[],{"intervention":1473,"totalTrials":91,"cells":1474},"Rapydan",{"EARLY_PHASE1":1475,"PHASE1":1477,"PHASE2":1479,"PHASE3":1481,"PHASE4":1483,"NA":1496},{"trials":1476,"activeCount":95},[],{"trials":1478,"activeCount":95},[],{"trials":1480,"activeCount":95},[],{"trials":1482,"activeCount":95},[],{"trials":1484,"activeCount":95},[1485],{"nctId":1486,"briefTitle":1487,"status":1155,"phases":1488,"primaryCompletion":1489,"start":1490,"enrollment":95,"conditions":1491,"interventions":1494},"NCT00670696","A Study to Compare the Efficacy of Rapydan Versus Tetracaine Gel",[87],"2008-12","2008-04",[1492,1493],"Healthy","Anesthesia",[1473,1495],"tetracaine gel",{"trials":1497,"activeCount":95},[],{"intervention":1495,"totalTrials":91,"cells":1499},{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1506,"PHASE4":1508,"NA":1514},{"trials":1501,"activeCount":95},[],{"trials":1503,"activeCount":95},[],{"trials":1505,"activeCount":95},[],{"trials":1507,"activeCount":95},[],{"trials":1509,"activeCount":95},[1510],{"nctId":1486,"briefTitle":1487,"status":1155,"phases":1511,"primaryCompletion":1489,"start":1490,"enrollment":95,"conditions":1512,"interventions":1513},[87],[1492,1493],[1473,1495],{"trials":1515,"activeCount":95},[],{"intervention":1517,"totalTrials":91,"cells":1518},"Cannabidiol Oral Solution [Epidiolex]",{"EARLY_PHASE1":1519,"PHASE1":1521,"PHASE2":1523,"PHASE3":1525,"PHASE4":1527,"NA":1539},{"trials":1520,"activeCount":95},[],{"trials":1522,"activeCount":95},[],{"trials":1524,"activeCount":95},[],{"trials":1526,"activeCount":95},[],{"trials":1528,"activeCount":95},[1529],{"nctId":1530,"briefTitle":1531,"status":161,"phases":1532,"primaryCompletion":1533,"completion":1533,"start":1534,"enrollment":1535,"conditions":1536,"interventions":1538},"NCT05864846","A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex",[87],"2026-04-06","2023-06-29",79,[1537],"Tuberous Sclerosis Complex Associated Neuropsychiatric Disease",[1517],{"trials":1540,"activeCount":95},[],{"intervention":1542,"totalTrials":118,"cells":1543},"JZP-110",{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1548,"PHASE3":1578,"PHASE4":1612,"NA":1614},{"trials":1545,"activeCount":95},[],{"trials":1547,"activeCount":95},[],{"trials":1549,"activeCount":95},[1550,1561,1570],{"nctId":1551,"briefTitle":1552,"status":161,"phases":1553,"primaryCompletion":1554,"completion":1554,"start":1555,"enrollment":1556,"conditions":1557,"interventions":1560},"NCT02806895","Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA",[85],"2019-05-28","2016-07-05",34,[1558,1559],"Obstructive Sleep Apnea","Excessive Sleepiness",[1542],{"nctId":1562,"briefTitle":1563,"status":161,"phases":1564,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1266,"conditions":1567,"interventions":1569},"NCT03037203","A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness",[85],"2018-08","2017-01",[1559,1568],"Parkinson Disease",[1542],{"nctId":1571,"briefTitle":1572,"status":161,"phases":1573,"primaryCompletion":1574,"completion":1574,"start":1208,"enrollment":1575,"conditions":1576,"interventions":1577},"NCT02806908","Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy",[85],"2019-05-19",24,[15,1559],[1542],{"trials":1579,"activeCount":95},[1580,1589,1596,1604],{"nctId":1581,"briefTitle":1582,"status":161,"phases":1583,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":1586,"conditions":1587,"interventions":1588},"NCT02348619","\"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA\"",[86],"2016-11","2015-05",174,[1558],[1542],{"nctId":1590,"briefTitle":1591,"status":161,"phases":1592,"primaryCompletion":1332,"completion":1332,"start":1585,"enrollment":1593,"conditions":1594,"interventions":1595},"NCT02348593","\"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy\"",[86],239,[15],[1542],{"nctId":1597,"briefTitle":1598,"status":161,"phases":1599,"primaryCompletion":1600,"completion":1600,"start":1585,"enrollment":1601,"conditions":1602,"interventions":1603},"NCT02348606","\"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA\"",[86],"2016-12",476,[1558],[1542],{"nctId":1605,"briefTitle":1606,"status":161,"phases":1607,"primaryCompletion":1608,"completion":1608,"start":1585,"enrollment":1609,"conditions":1610,"interventions":1611},"NCT02348632","\"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA\"",[86],"2017-12",645,[15,1558],[1542],{"trials":1613,"activeCount":95},[],{"trials":1615,"activeCount":95},[],{"intervention":1617,"totalTrials":118,"cells":1618},"Nabiximols",{"EARLY_PHASE1":1619,"PHASE1":1621,"PHASE2":1623,"PHASE3":1625,"PHASE4":1696,"NA":1698},{"trials":1620,"activeCount":95},[],{"trials":1622,"activeCount":95},[],{"trials":1624,"activeCount":95},[],{"trials":1626,"activeCount":95},[1627,1637,1648,1657,1668,1677,1686],{"nctId":1628,"briefTitle":1629,"status":317,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1633,"conditions":1634,"interventions":1636},"NCT04984278","Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis",[86],"2022-11-11","2021-08-16",56,[1635],"Spasticity With Multiple Sclerosis",[1617],{"nctId":1638,"briefTitle":1639,"status":161,"phases":1640,"primaryCompletion":1641,"completion":1642,"start":1643,"enrollment":1644,"conditions":1645,"interventions":1647},"NCT04657666","Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis",[86],"2022-05-04","2022-05-10","2020-12-21",68,[1646],"Spasticity in Participants With Multiple Sclerosis",[1617],{"nctId":1649,"briefTitle":1650,"status":161,"phases":1651,"primaryCompletion":1652,"completion":1652,"start":1653,"enrollment":1654,"conditions":1655,"interventions":1656},"NCT01361607","Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer",[86],"2014-11-24","2011-05-27",399,[20,894],[1617],{"nctId":1658,"briefTitle":1659,"status":317,"phases":1660,"primaryCompletion":1661,"completion":1662,"start":1663,"enrollment":1664,"conditions":1665,"interventions":1667},"NCT04203498","Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis",[86],"2023-02-10","2023-02-28","2020-10-01",139,[1666],"Multiple Sclerosis (MS)",[1617],{"nctId":1669,"briefTitle":1670,"status":161,"phases":1671,"primaryCompletion":1672,"completion":1672,"start":1673,"enrollment":1674,"conditions":1675,"interventions":1676},"NCT01337089","Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain",[86],"2016-01-27","2011-01-19",660,[20,894],[1617],{"nctId":1678,"briefTitle":1679,"status":1155,"phases":1680,"primaryCompletion":1681,"completion":1681,"start":1682,"enrollment":95,"conditions":1683,"interventions":1685},"NCT04592159","Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder",[85,86],"2023-03","2021-02-01",[1684],"Post-Traumatic Stress Disorder",[1617],{"nctId":1687,"briefTitle":1688,"status":161,"phases":1689,"primaryCompletion":1690,"completion":1691,"start":1692,"enrollment":1693,"conditions":1694,"interventions":1695},"NCT01424566","A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer",[86],"2015-07-10","2015-12-28","2012-06-29",406,[20,894],[1617],{"trials":1697,"activeCount":95},[],{"trials":1699,"activeCount":95},[],{"intervention":1701,"totalTrials":118,"cells":1702},"GW-1000-02",{"EARLY_PHASE1":1703,"PHASE1":1705,"PHASE2":1707,"PHASE3":1709,"PHASE4":1768,"NA":1770},{"trials":1704,"activeCount":95},[],{"trials":1706,"activeCount":95},[],{"trials":1708,"activeCount":95},[],{"trials":1710,"activeCount":95},[1711,1720,1729,1738,1745,1753,1762],{"nctId":1712,"briefTitle":1713,"status":161,"phases":1714,"primaryCompletion":1715,"completion":1715,"start":1716,"enrollment":1717,"conditions":1718,"interventions":1719},"NCT01606137","A Study of the Long-term Safety of Sativex Use",[86],"2004-12","2002-02",507,[22,28,20],[1701],{"nctId":1721,"briefTitle":1722,"status":161,"phases":1723,"primaryCompletion":1724,"completion":1724,"start":1725,"enrollment":1726,"conditions":1727,"interventions":1728},"NCT01606189","A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain",[86],"2002-09","2001-12",48,[20],[1701,1231],{"nctId":1730,"briefTitle":1731,"status":161,"phases":1732,"primaryCompletion":1733,"completion":1733,"start":1734,"enrollment":1735,"conditions":1736,"interventions":1737},"NCT01606202","A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury",[86],"2005-01","2002-07",116,[20],[1701],{"nctId":1739,"briefTitle":1740,"status":161,"phases":1741,"primaryCompletion":1264,"completion":1264,"start":1265,"enrollment":1742,"conditions":1743,"interventions":1744},"NCT01606176","A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin",[86],70,[20,22],[1701],{"nctId":1746,"briefTitle":1747,"status":161,"phases":1748,"primaryCompletion":1734,"completion":1734,"start":1749,"enrollment":1750,"conditions":1751,"interventions":1752},"NCT01610700","An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients",[86],"2001-05",160,[22],[1701],{"nctId":1754,"briefTitle":1755,"status":161,"phases":1756,"primaryCompletion":1757,"completion":1757,"start":1758,"enrollment":1759,"conditions":1760,"interventions":1761},"NCT01610687","A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis",[86],"2005-02","2001-07",137,[22,28],[1701],{"nctId":1763,"briefTitle":1764,"status":161,"phases":1765,"primaryCompletion":1734,"completion":1734,"start":1749,"enrollment":109,"conditions":1766,"interventions":1767},"NCT01610713","An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis",[86],[22],[1701],{"trials":1769,"activeCount":95},[],{"trials":1771,"activeCount":95},[],{"intervention":1773,"totalTrials":12,"cells":1774},"Defibrotide",{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1779,"PHASE3":1804,"PHASE4":1836,"NA":1838},{"trials":1776,"activeCount":95},[],{"trials":1778,"activeCount":95},[],{"trials":1780,"activeCount":95},[1781,1793],{"nctId":1782,"briefTitle":1783,"status":161,"phases":1784,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1787,"conditions":1788,"interventions":1791},"NCT03339297","An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)",[85],"2020-05-12","2018-02-21",152,[1789,1790],"Graft-versus-host Disease","Acute-graft-versus-host Disease",[1773,1792],"Standard of Care",{"nctId":1794,"briefTitle":1795,"status":317,"phases":1796,"primaryCompletion":1797,"completion":1798,"start":1799,"enrollment":1187,"conditions":1800,"interventions":1803},"NCT03954106","A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity",[85],"2020-09-18","2020-09-30","2019-10-04",[1801,1802],"DLBCL","Neurotoxicity Syndromes",[1773],{"trials":1805,"activeCount":95},[1806,1816,1826],{"nctId":1807,"briefTitle":1808,"status":161,"phases":1809,"primaryCompletion":1810,"completion":1811,"start":1812,"enrollment":440,"conditions":1813,"interventions":1815},"NCT00358501","Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients",[86],"2008-09","2015-03","2006-07",[1814],"Severe Hepatic Veno-Occlusive Disease",[1773],{"nctId":1817,"briefTitle":1818,"status":161,"phases":1819,"primaryCompletion":1820,"completion":1820,"start":1821,"enrollment":1822,"conditions":1823,"interventions":1825},"NCT02851407","Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients",[86],"2020-10-20","2016-09-01",372,[1824],"Veno-occlusive Disease",[1773],{"nctId":1827,"briefTitle":1828,"status":161,"phases":1829,"primaryCompletion":1830,"completion":1284,"start":1831,"enrollment":1832,"conditions":1833,"interventions":1835},"NCT00628498","Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study",[86],"2016-07","2007-12",1206,[1834],"Hepatic Veno-Occlusive Disease",[1773,1773],{"trials":1837,"activeCount":95},[],{"trials":1839,"activeCount":95},[],{"intervention":1841,"totalTrials":256,"cells":1842},"GWP42003-P 20 mg\u002Fkg\u002Fday Dose",{"EARLY_PHASE1":1843,"PHASE1":1845,"PHASE2":1847,"PHASE3":1868,"PHASE4":1888,"NA":1890},{"trials":1844,"activeCount":95},[],{"trials":1846,"activeCount":95},[],{"trials":1848,"activeCount":95},[1849,1858],{"nctId":1850,"briefTitle":1851,"status":161,"phases":1852,"primaryCompletion":1853,"completion":1853,"start":1854,"enrollment":8,"conditions":1855,"interventions":1856},"NCT02565108","A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol",[85],"2016-07-21","2016-01-20",[18],[1857,1035],"GWP42003-P 20 mg\u002Fkg\u002FDay Dose",{"nctId":1859,"briefTitle":1860,"status":161,"phases":1861,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":1556,"conditions":1864,"interventions":1865},"NCT02091206","A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)",[85],"2015-03-09","2014-10-22",[18,112],[1866,1867,1841],"GWP42003-P 5 mg\u002Fkg\u002Fday Dose","GWP42003-P 10 mg\u002Fkg\u002Fday Dose",{"trials":1869,"activeCount":95},[1870,1879],{"nctId":1871,"briefTitle":1872,"status":161,"phases":1873,"primaryCompletion":1874,"completion":1874,"start":1875,"enrollment":1876,"conditions":1877,"interventions":1878},"NCT02224690","A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults",[86],"2016-03-18","2015-04-28",171,[18,1160],[1841],{"nctId":1880,"briefTitle":1881,"status":161,"phases":1882,"primaryCompletion":1883,"completion":1883,"start":1884,"enrollment":1885,"conditions":1886,"interventions":1887},"NCT02091375","Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)",[86],"2015-11-26","2015-03-30",120,[18,112],[1841],{"trials":1889,"activeCount":95},[],{"trials":1891,"activeCount":95},[],{"intervention":1893,"totalTrials":216,"cells":1894},"Xyrem®",{"EARLY_PHASE1":1895,"PHASE1":1897,"PHASE2":1899,"PHASE3":1901,"PHASE4":1929,"NA":1931},{"trials":1896,"activeCount":95},[],{"trials":1898,"activeCount":95},[],{"trials":1900,"activeCount":95},[],{"trials":1902,"activeCount":95},[1903,1912,1921],{"nctId":1904,"briefTitle":1905,"status":161,"phases":1906,"primaryCompletion":1907,"completion":1907,"start":1908,"enrollment":1909,"conditions":1910,"interventions":1911},"NCT00423605","Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.",[86],"2010-01","2006-12",560,[33],[1893],{"nctId":1913,"briefTitle":1914,"status":161,"phases":1915,"primaryCompletion":1916,"completion":1917,"start":1908,"enrollment":1918,"conditions":1919,"interventions":1920},"NCT00423813","A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.",[86],"2009-04","2009-06",573,[33],[1893],{"nctId":1922,"briefTitle":1923,"status":161,"phases":1924,"primaryCompletion":1810,"completion":1489,"start":1925,"enrollment":1926,"conditions":1927,"interventions":1928},"NCT00371137","A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia",[86],"2006-08",548,[33],[1893],{"trials":1930,"activeCount":95},[],{"trials":1932,"activeCount":95},[],{"intervention":1934,"totalTrials":216,"cells":1935},"Dociparstat sodium",{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1948,"PHASE3":1961,"PHASE4":1974,"NA":1976},{"trials":1937,"activeCount":95},[],{"trials":1939,"activeCount":95},[1940],{"nctId":1941,"briefTitle":1942,"status":161,"phases":1943,"primaryCompletion":1944,"completion":320,"start":1286,"enrollment":1945,"conditions":1946,"interventions":1947},"NCT02056782","A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia",[84],"2015-02",12,[25],[1934],{"trials":1949,"activeCount":95},[1950],{"nctId":1951,"briefTitle":1952,"status":161,"phases":1953,"primaryCompletion":1954,"completion":1954,"start":1955,"enrollment":1956,"conditions":1957,"interventions":1958},"NCT02873338","Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia",[85],"2019-06","2016-08",75,[25],[1934,1959,1960],"Idarubicin","Cytarabine",{"trials":1962,"activeCount":95},[1963],{"nctId":1964,"briefTitle":1965,"status":317,"phases":1966,"primaryCompletion":1967,"completion":1967,"start":1968,"enrollment":478,"conditions":1969,"interventions":1973},"NCT04389840","Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure",[85,86],"2021-05-20","2020-07-08",[1970,1971,1972],"Coronavirus Disease 2019 (COVID-19)","Acute Lung Injury","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)",[1934],{"trials":1975,"activeCount":95},[],{"trials":1977,"activeCount":95},[],{"intervention":1979,"totalTrials":171,"cells":1980},"Xyrem (sodium oxybate) oral solution",{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1985,"PHASE3":1996,"PHASE4":2007,"NA":2009},{"trials":1982,"activeCount":95},[],{"trials":1984,"activeCount":95},[],{"trials":1986,"activeCount":95},[1987],{"nctId":1988,"briefTitle":1989,"status":161,"phases":1990,"primaryCompletion":1991,"completion":1992,"start":1319,"enrollment":1993,"conditions":1994,"interventions":1995},"NCT00087555","Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia",[85],"2005-04","2006-01",195,[33],[1979,1979],{"trials":1997,"activeCount":95},[1998],{"nctId":1999,"briefTitle":2000,"status":161,"phases":2001,"primaryCompletion":2002,"completion":1831,"start":2003,"enrollment":2004,"conditions":2005,"interventions":2006},"NCT00132873","Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy",[86],"2007-09","2004-10",59,[15],[1979],{"trials":2008,"activeCount":95},[],{"trials":2010,"activeCount":95},[],{"intervention":1231,"totalTrials":171,"cells":2012},{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2019,"PHASE4":2029,"NA":2031},{"trials":2014,"activeCount":95},[],{"trials":2016,"activeCount":95},[],{"trials":2018,"activeCount":95},[],{"trials":2020,"activeCount":95},[2021,2025],{"nctId":1721,"briefTitle":1722,"status":161,"phases":2022,"primaryCompletion":1724,"completion":1724,"start":1725,"enrollment":1726,"conditions":2023,"interventions":2024},[86],[20],[1701,1231],{"nctId":1223,"briefTitle":1224,"status":161,"phases":2026,"primaryCompletion":1226,"completion":1226,"start":1227,"enrollment":1228,"conditions":2027,"interventions":2028},[86],[20,1211],[1165,1231],{"trials":2030,"activeCount":95},[],{"trials":2032,"activeCount":95},[],{"intervention":327,"totalTrials":171,"cells":2034},{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2039,"PHASE3":2045,"PHASE4":2055,"NA":2057},{"trials":2036,"activeCount":95},[],{"trials":2038,"activeCount":95},[],{"trials":2040,"activeCount":95},[2041],{"nctId":315,"briefTitle":316,"status":317,"phases":2042,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":2043,"interventions":2044},[85],[324],[326,187,327],{"trials":2046,"activeCount":95},[2047],{"nctId":2048,"briefTitle":2049,"status":317,"phases":2050,"primaryCompletion":2051,"completion":2051,"start":2052,"enrollment":1112,"conditions":2053,"interventions":2054},"NCT04571645","Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia",[86],"2022-05-16","2021-04-30",[25],[327],{"trials":2056,"activeCount":95},[],{"trials":2058,"activeCount":95},[],{"intervention":2060,"totalTrials":171,"cells":2061},"Valganciclovir",{"EARLY_PHASE1":2062,"PHASE1":2064,"PHASE2":2066,"PHASE3":2068,"PHASE4":2089,"NA":2091},{"trials":2063,"activeCount":95},[],{"trials":2065,"activeCount":95},[],{"trials":2067,"activeCount":95},[],{"trials":2069,"activeCount":95},[2070,2080],{"nctId":2071,"briefTitle":2072,"status":317,"phases":2073,"primaryCompletion":2074,"completion":2074,"start":2075,"enrollment":12,"conditions":2076,"interventions":2078},"NCT02439970","A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease",[86],"2016-01-30","2015-09",[2077],"Cytomegalovirus Disease",[2079,2060],"Brincidofovir",{"nctId":2081,"briefTitle":2082,"status":317,"phases":2083,"primaryCompletion":2084,"completion":2085,"start":2075,"enrollment":29,"conditions":2086,"interventions":2088},"NCT02439957","A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus",[86],"2016-05-15","2016-07-31",[2077,2087],"Kidney Transplant Infection",[2079,2060],{"trials":2090,"activeCount":95},[],{"trials":2092,"activeCount":95},[],{"intervention":2094,"totalTrials":171,"cells":2095},"Sodium Oxybate",{"EARLY_PHASE1":2096,"PHASE1":2098,"PHASE2":2100,"PHASE3":2111,"PHASE4":2125,"NA":2127},{"trials":2097,"activeCount":95},[],{"trials":2099,"activeCount":95},[],{"trials":2101,"activeCount":95},[2102],{"nctId":2103,"briefTitle":2104,"status":161,"phases":2105,"primaryCompletion":2106,"completion":1489,"start":1831,"enrollment":2107,"conditions":2108,"interventions":2110},"NCT00598078","Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor",[85],"2008-08",19,[2109],"Essential Tremor",[2094,2094],{"trials":2112,"activeCount":95},[2113],{"nctId":2114,"briefTitle":2115,"status":161,"phases":2116,"primaryCompletion":2117,"start":2118,"enrollment":2119,"conditions":2120,"interventions":2121},"NCT00803023","Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia",[86],"2010-07","2010-03",129,[33],[2094,2122,2123,2124],"Sodium Oxybate & 6","Sodium Oxybate & 8","Sodium Oxybate Oral Solution",{"trials":2126,"activeCount":95},[],{"trials":2128,"activeCount":95},[],{"intervention":2130,"totalTrials":91,"cells":2131},"IM JZP-458",{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2138,"PHASE4":2151,"NA":2153},{"trials":2133,"activeCount":95},[],{"trials":2135,"activeCount":95},[],{"trials":2137,"activeCount":95},[],{"trials":2139,"activeCount":95},[2140],{"nctId":2141,"briefTitle":2142,"status":161,"phases":2143,"primaryCompletion":2144,"completion":2144,"start":2145,"enrollment":2146,"conditions":2147,"interventions":2149},"NCT04145531","An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)\u002FLymphoblastic Lymphoma (LBL)",[85,86],"2022-07-13","2019-12-27",229,[31,2148],"Lymphoblastic Leukemia",[2130,2150],"IV JZP-458",{"trials":2152,"activeCount":95},[],{"trials":2154,"activeCount":95},[],{"intervention":2150,"totalTrials":91,"cells":2156},{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2161,"PHASE3":2163,"PHASE4":2169,"NA":2171},{"trials":2158,"activeCount":95},[],{"trials":2160,"activeCount":95},[],{"trials":2162,"activeCount":95},[],{"trials":2164,"activeCount":95},[2165],{"nctId":2141,"briefTitle":2142,"status":161,"phases":2166,"primaryCompletion":2144,"completion":2144,"start":2145,"enrollment":2146,"conditions":2167,"interventions":2168},[85,86],[31,2148],[2130,2150],{"trials":2170,"activeCount":95},[],{"trials":2172,"activeCount":95},[],{"intervention":1325,"totalTrials":91,"cells":2174},{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2181,"PHASE4":2187,"NA":2189},{"trials":2176,"activeCount":95},[],{"trials":2178,"activeCount":95},[],{"trials":2180,"activeCount":95},[],{"trials":2182,"activeCount":95},[2183],{"nctId":1316,"briefTitle":1317,"status":161,"phases":2184,"primaryCompletion":1319,"completion":1320,"start":1321,"enrollment":1322,"conditions":2185,"interventions":2186},[86],[15],[1305,1325,1326,1327],{"trials":2188,"activeCount":95},[],{"trials":2190,"activeCount":95},[],{"intervention":1326,"totalTrials":91,"cells":2192},{"EARLY_PHASE1":2193,"PHASE1":2195,"PHASE2":2197,"PHASE3":2199,"PHASE4":2205,"NA":2207},{"trials":2194,"activeCount":95},[],{"trials":2196,"activeCount":95},[],{"trials":2198,"activeCount":95},[],{"trials":2200,"activeCount":95},[2201],{"nctId":1316,"briefTitle":1317,"status":161,"phases":2202,"primaryCompletion":1319,"completion":1320,"start":1321,"enrollment":1322,"conditions":2203,"interventions":2204},[86],[15],[1305,1325,1326,1327],{"trials":2206,"activeCount":95},[],{"trials":2208,"activeCount":95},[],{"intervention":2210,"totalTrials":91,"cells":2211},"a benzodiazepine drug",{"EARLY_PHASE1":2212,"PHASE1":2214,"PHASE2":2216,"PHASE3":2218,"PHASE4":2228,"NA":2230},{"trials":2213,"activeCount":95},[],{"trials":2215,"activeCount":95},[],{"trials":2217,"activeCount":95},[],{"trials":2219,"activeCount":95},[2220],{"nctId":2221,"briefTitle":2222,"status":161,"phases":2223,"completion":2224,"start":1256,"enrollment":973,"conditions":2225,"interventions":2227},"NCT00106860","A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder",[86],"2006-03",[2226],"Anxiety Disorder",[2210],{"trials":2229,"activeCount":95},[],{"trials":2231,"activeCount":95},[],{"intervention":2122,"totalTrials":91,"cells":2233},{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2238,"PHASE3":2240,"PHASE4":2246,"NA":2248},{"trials":2235,"activeCount":95},[],{"trials":2237,"activeCount":95},[],{"trials":2239,"activeCount":95},[],{"trials":2241,"activeCount":95},[2242],{"nctId":2114,"briefTitle":2115,"status":161,"phases":2243,"primaryCompletion":2117,"start":2118,"enrollment":2119,"conditions":2244,"interventions":2245},[86],[33],[2094,2122,2123,2124],{"trials":2247,"activeCount":95},[],{"trials":2249,"activeCount":95},[],{"intervention":2123,"totalTrials":91,"cells":2251},{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2256,"PHASE3":2258,"PHASE4":2264,"NA":2266},{"trials":2253,"activeCount":95},[],{"trials":2255,"activeCount":95},[],{"trials":2257,"activeCount":95},[],{"trials":2259,"activeCount":95},[2260],{"nctId":2114,"briefTitle":2115,"status":161,"phases":2261,"primaryCompletion":2117,"start":2118,"enrollment":2119,"conditions":2262,"interventions":2263},[86],[33],[2094,2122,2123,2124],{"trials":2265,"activeCount":95},[],{"trials":2267,"activeCount":95},[],{"intervention":2124,"totalTrials":91,"cells":2269},{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2274,"PHASE3":2276,"PHASE4":2282,"NA":2284},{"trials":2271,"activeCount":95},[],{"trials":2273,"activeCount":95},[],{"trials":2275,"activeCount":95},[],{"trials":2277,"activeCount":95},[2278],{"nctId":2114,"briefTitle":2115,"status":161,"phases":2279,"primaryCompletion":2117,"start":2118,"enrollment":2119,"conditions":2280,"interventions":2281},[86],[33],[2094,2122,2123,2124],{"trials":2283,"activeCount":95},[],{"trials":2285,"activeCount":95},[],{"intervention":2287,"totalTrials":91,"cells":2288},"THC Alone",{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2293,"PHASE3":2295,"PHASE4":2307,"NA":2309},{"trials":2290,"activeCount":95},[],{"trials":2292,"activeCount":95},[],{"trials":2294,"activeCount":95},[],{"trials":2296,"activeCount":95},[2297],{"nctId":2298,"briefTitle":2299,"status":161,"phases":2300,"primaryCompletion":2301,"completion":2302,"start":1716,"enrollment":378,"conditions":2303,"interventions":2305},"NCT00674609","A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy",[86],"2004-02","2004-03",[2304,20,1211],"Palliative Care",[2306,2287],"Sativex®",{"trials":2308,"activeCount":95},[],{"trials":2310,"activeCount":95},[],{"intervention":2312,"totalTrials":91,"cells":2313},"experimental anti-anxiety drug",{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2318,"PHASE3":2320,"PHASE4":2329,"NA":2331},{"trials":2315,"activeCount":95},[],{"trials":2317,"activeCount":95},[],{"trials":2319,"activeCount":95},[],{"trials":2321,"activeCount":95},[2322],{"nctId":2323,"briefTitle":2324,"status":161,"phases":2325,"completion":1255,"start":1320,"enrollment":2326,"conditions":2327,"interventions":2328},"NCT00097708","Experimental Medication For the Treatment of Generalized Anxiety Disorder",[86],511,[2226],[2312],{"trials":2330,"activeCount":95},[],{"trials":2332,"activeCount":95},[],{"intervention":2334,"totalTrials":91,"cells":2335},"7+3",{"EARLY_PHASE1":2336,"PHASE1":2338,"PHASE2":2340,"PHASE3":2342,"PHASE4":2355,"NA":2357},{"trials":2337,"activeCount":95},[],{"trials":2339,"activeCount":95},[],{"trials":2341,"activeCount":95},[],{"trials":2343,"activeCount":95},[2344],{"nctId":2345,"briefTitle":2346,"status":161,"phases":2347,"primaryCompletion":2348,"completion":2348,"start":2349,"enrollment":2350,"conditions":2351,"interventions":2353},"NCT01696084","Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia",[86],"2015-12-31","2012-12-13",309,[2352],"High Risk Acute Myeloid Leukemia",[2354,2334],"CPX-351",{"trials":2356,"activeCount":95},[],{"trials":2358,"activeCount":95},[],{"intervention":271,"totalTrials":256,"cells":2360},{"EARLY_PHASE1":2361,"PHASE1":2363,"PHASE2":2369,"PHASE3":2398,"PHASE4":2400,"NA":2402},{"trials":2362,"activeCount":95},[],{"trials":2364,"activeCount":95},[2365],{"nctId":263,"briefTitle":264,"status":161,"phases":2366,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":2367,"interventions":2368},[84],[168],[271,136,188,186,272,272],{"trials":2370,"activeCount":95},[2371,2375,2385],{"nctId":276,"briefTitle":277,"status":161,"phases":2372,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":2373,"interventions":2374},[85],[283],[271,188,200,285,286,214,287,187],{"nctId":2376,"briefTitle":2377,"status":161,"phases":2378,"primaryCompletion":2379,"completion":2380,"start":1663,"enrollment":2381,"conditions":2382,"interventions":2384},"NCT04466891","A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers",[85],"2023-07-28","2024-07-11",87,[2383],"HER2-amplified Biliary Tract Cancers",[271],{"nctId":2386,"briefTitle":2387,"status":161,"phases":2388,"primaryCompletion":2389,"completion":2390,"start":2391,"enrollment":2392,"conditions":2393,"interventions":2395},"NCT04224272","A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+\u002FHR+ Advanced Breast Cancer",[85],"2023-04-28","2025-06-30","2020-06-10",51,[2394],"HER2+\u002FHR+ Breast Cancer",[271,2396,2397],"Palbociclib","Fulvestrant",{"trials":2399,"activeCount":95},[],{"trials":2401,"activeCount":95},[],{"trials":2403,"activeCount":95},[],{"intervention":2405,"totalTrials":256,"cells":2406},"GWP42006",{"EARLY_PHASE1":2407,"PHASE1":2409,"PHASE2":2418,"PHASE3":2446,"PHASE4":2448,"NA":2450},{"trials":2408,"activeCount":95},[],{"trials":2410,"activeCount":95},[2411],{"nctId":2412,"briefTitle":2413,"status":161,"phases":2414,"primaryCompletion":1286,"completion":1286,"start":2415,"enrollment":1266,"conditions":2416,"interventions":2417},"NCT01918735","A Study of the Safety and Tolerability of GWP42006 in Healthy Subjects",[84],"2013-08",[18],[2405],{"trials":2419,"activeCount":95},[2420,2428,2438],{"nctId":2421,"briefTitle":2422,"status":317,"phases":2423,"primaryCompletion":2424,"completion":2424,"start":2425,"enrollment":91,"conditions":2426,"interventions":2427},"NCT03849456","Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder",[85],"2020-05-26","2020-01-07",[1044],[2405],{"nctId":2429,"briefTitle":2430,"status":161,"phases":2431,"primaryCompletion":2432,"completion":2433,"start":2434,"enrollment":2435,"conditions":2436,"interventions":2437},"NCT02365610","A Study of GWP42006 in People With Focal Seizures - Part B",[85],"2017-07","2017-09","2016-03",162,[18,869],[2405],{"nctId":2439,"briefTitle":2440,"status":161,"phases":2441,"primaryCompletion":2442,"completion":2443,"start":1811,"enrollment":1197,"conditions":2444,"interventions":2445},"NCT02369471","A Study of GWP42006 in People With Focal Seizures - Part A",[85],"2015-10","2015-11",[18,869],[2405],{"trials":2447,"activeCount":95},[],{"trials":2449,"activeCount":95},[],{"trials":2451,"activeCount":95},[],{"intervention":2453,"totalTrials":216,"cells":2454},"CX-8998",{"EARLY_PHASE1":2455,"PHASE1":2457,"PHASE2":2459,"PHASE3":2488,"PHASE4":2490,"NA":2492},{"trials":2456,"activeCount":95},[],{"trials":2458,"activeCount":95},[],{"trials":2460,"activeCount":95},[2461,2469,2480],{"nctId":2462,"briefTitle":2463,"status":161,"phases":2464,"primaryCompletion":2465,"completion":2465,"start":2466,"enrollment":118,"conditions":2467,"interventions":2468},"NCT03406702","CX-8998 for Absence Seizures",[85],"2019-03-29","2018-02-25",[18],[2453],{"nctId":2470,"briefTitle":2471,"status":1155,"phases":2472,"primaryCompletion":2473,"completion":2474,"start":2475,"enrollment":95,"conditions":2476,"interventions":2479},"NCT03436953","A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease",[85],"2020-09","2020-12","2019-12",[2477,2478],"Parkinson's Disease","Tremor",[2453],{"nctId":2481,"briefTitle":2482,"status":161,"phases":2483,"primaryCompletion":2484,"completion":2484,"start":2485,"enrollment":1012,"conditions":2486,"interventions":2487},"NCT03101241","A Phase 2 RCT Study of CX-8998 for Essential Tremor",[85],"2018-07-16","2017-08-29",[2109],[2453],{"trials":2489,"activeCount":95},[],{"trials":2491,"activeCount":95},[],{"trials":2493,"activeCount":95},[],{"intervention":2495,"totalTrials":171,"cells":2496},"ODSH",{"EARLY_PHASE1":2497,"PHASE1":2506,"PHASE2":2508,"PHASE3":2521,"PHASE4":2523,"NA":2525},{"trials":2498,"activeCount":95},[2499],{"nctId":2500,"briefTitle":2501,"status":161,"phases":2502,"primaryCompletion":2503,"completion":2503,"start":2415,"enrollment":26,"conditions":2504,"interventions":2505},"NCT01843634","Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia",[83],"2015-04",[25],[2495],{"trials":2507,"activeCount":95},[],{"trials":2509,"activeCount":95},[2510],{"nctId":2511,"briefTitle":2512,"status":317,"phases":2513,"primaryCompletion":2514,"completion":2515,"start":2516,"enrollment":973,"conditions":2517,"interventions":2519},"NCT00457951","A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD",[85],"2009-08","2009-10","2007-04",[2518],"Chronic Obstructive Pulmonary Disease",[2520,2495],"Open-Label",{"trials":2522,"activeCount":95},[],{"trials":2524,"activeCount":95},[],{"trials":2526,"activeCount":95},[],{"intervention":2528,"totalTrials":171,"cells":2529},"GWP42003",{"EARLY_PHASE1":2530,"PHASE1":2532,"PHASE2":2534,"PHASE3":2558,"PHASE4":2560,"NA":2562},{"trials":2531,"activeCount":95},[],{"trials":2533,"activeCount":95},[],{"trials":2535,"activeCount":95},[2536,2546],{"nctId":2537,"briefTitle":2538,"status":161,"phases":2539,"primaryCompletion":2540,"completion":2540,"start":2541,"enrollment":2542,"conditions":2543,"interventions":2545},"NCT02006628","A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder",[85],"2015-01-08","2014-02-25",88,[1014,2544],"Schizophrenia-related Psychotic Disorder",[2528],{"nctId":2547,"briefTitle":2548,"status":161,"phases":2549,"primaryCompletion":2550,"completion":2551,"start":2552,"enrollment":1393,"conditions":2553,"interventions":2556},"NCT01217112","GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes",[85],"2012-05","2012-09","2010-10",[2554,2555],"Dyslipidemias","Diabetes Mellitus, Type 2",[2528,2528,2557],"GWP42004",{"trials":2559,"activeCount":95},[],{"trials":2561,"activeCount":95},[],{"trials":2563,"activeCount":95},[],{"intervention":1035,"totalTrials":171,"cells":2565},{"EARLY_PHASE1":2566,"PHASE1":2568,"PHASE2":2570,"PHASE3":2580,"PHASE4":2582,"NA":2584},{"trials":2567,"activeCount":95},[],{"trials":2569,"activeCount":95},[],{"trials":2571,"activeCount":95},[2572,2576],{"nctId":1850,"briefTitle":1851,"status":161,"phases":2573,"primaryCompletion":1853,"completion":1853,"start":1854,"enrollment":8,"conditions":2574,"interventions":2575},[85],[18],[1857,1035],{"nctId":1027,"briefTitle":1028,"status":161,"phases":2577,"primaryCompletion":1030,"completion":1030,"start":1031,"enrollment":1032,"conditions":2578,"interventions":2579},[85],[18],[997,1035],{"trials":2581,"activeCount":95},[],{"trials":2583,"activeCount":95},[],{"trials":2585,"activeCount":95},[],{"intervention":1792,"totalTrials":171,"cells":2587},{"EARLY_PHASE1":2588,"PHASE1":2590,"PHASE2":2592,"PHASE3":2607,"PHASE4":2609,"NA":2611},{"trials":2589,"activeCount":95},[],{"trials":2591,"activeCount":95},[],{"trials":2593,"activeCount":95},[2594,2598],{"nctId":1782,"briefTitle":1783,"status":161,"phases":2595,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1787,"conditions":2596,"interventions":2597},[85],[1789,1790],[1773,1792],{"nctId":2599,"briefTitle":2600,"status":1155,"phases":2601,"primaryCompletion":2602,"completion":2602,"start":2603,"enrollment":95,"conditions":2604,"interventions":2606},"NCT03532035","Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia",[85],"2019-05-10","2018-12-15",[2605],"Adenovirus",[2079,1792],{"trials":2608,"activeCount":95},[],{"trials":2610,"activeCount":95},[],{"trials":2612,"activeCount":95},[],{"intervention":2614,"totalTrials":171,"cells":2615},"ADX-N05",{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2637,"PHASE4":2639,"NA":2641},{"trials":2617,"activeCount":95},[],{"trials":2619,"activeCount":95},[],{"trials":2621,"activeCount":95},[2622,2629],{"nctId":2623,"briefTitle":2624,"status":161,"phases":2625,"primaryCompletion":2415,"completion":2415,"start":2551,"enrollment":2626,"conditions":2627,"interventions":2628},"NCT01681121","A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy",[85],93,[15],[2614],{"nctId":2630,"briefTitle":2631,"status":161,"phases":2632,"primaryCompletion":2550,"completion":2550,"start":2633,"enrollment":2634,"conditions":2635,"interventions":2636},"NCT01485770","A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness",[85],"2011-12",33,[15],[2614],{"trials":2638,"activeCount":95},[],{"trials":2640,"activeCount":95},[],{"trials":2642,"activeCount":95},[],{"intervention":1960,"totalTrials":171,"cells":2644},{"EARLY_PHASE1":2645,"PHASE1":2647,"PHASE2":2649,"PHASE3":2665,"PHASE4":2667,"NA":2669},{"trials":2646,"activeCount":95},[],{"trials":2648,"activeCount":95},[],{"trials":2650,"activeCount":95},[2651,2655],{"nctId":1951,"briefTitle":1952,"status":161,"phases":2652,"primaryCompletion":1954,"completion":1954,"start":1955,"enrollment":1956,"conditions":2653,"interventions":2654},[85],[25],[1934,1959,1960],{"nctId":2656,"briefTitle":2657,"status":161,"phases":2658,"primaryCompletion":2659,"completion":2633,"start":2660,"enrollment":2661,"conditions":2662,"interventions":2663},"NCT00788892","Trial of CPX-351 in Newly Diagnosed Elderly AML Patients",[85],"2010-06","2008-10",126,[25],[2354,1960,2664],"Daunorubicin",{"trials":2666,"activeCount":95},[],{"trials":2668,"activeCount":95},[],{"trials":2670,"activeCount":95},[],{"intervention":2557,"totalTrials":171,"cells":2672},{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2677,"PHASE3":2691,"PHASE4":2693,"NA":2695},{"trials":2674,"activeCount":95},[],{"trials":2676,"activeCount":95},[],{"trials":2678,"activeCount":95},[2679,2687],{"nctId":2680,"briefTitle":2681,"status":161,"phases":2682,"primaryCompletion":2683,"completion":2683,"start":2684,"enrollment":1439,"conditions":2685,"interventions":2686},"NCT02053272","A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes",[85],"2016-02","2014-02",[2555],[2557],{"nctId":2547,"briefTitle":2548,"status":161,"phases":2688,"primaryCompletion":2550,"completion":2551,"start":2552,"enrollment":1393,"conditions":2689,"interventions":2690},[85],[2554,2555],[2528,2528,2557],{"trials":2692,"activeCount":95},[],{"trials":2694,"activeCount":95},[],{"trials":2696,"activeCount":95},[],{"intervention":2698,"totalTrials":91,"cells":2699},"Intensive Salvage Therapy",{"EARLY_PHASE1":2700,"PHASE1":2702,"PHASE2":2704,"PHASE3":2713,"PHASE4":2715,"NA":2717},{"trials":2701,"activeCount":95},[],{"trials":2703,"activeCount":95},[],{"trials":2705,"activeCount":95},[2706],{"nctId":2707,"briefTitle":2708,"status":161,"phases":2709,"primaryCompletion":2633,"completion":1298,"start":2710,"enrollment":2661,"conditions":2711,"interventions":2712},"NCT00822094","Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)",[85],"2009-02",[25],[2354,2698],{"trials":2714,"activeCount":95},[],{"trials":2716,"activeCount":95},[],{"trials":2718,"activeCount":95},[],{"intervention":285,"totalTrials":91,"cells":2720},{"EARLY_PHASE1":2721,"PHASE1":2723,"PHASE2":2725,"PHASE3":2731,"PHASE4":2733,"NA":2735},{"trials":2722,"activeCount":95},[],{"trials":2724,"activeCount":95},[],{"trials":2726,"activeCount":95},[2727],{"nctId":276,"briefTitle":277,"status":161,"phases":2728,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":2729,"interventions":2730},[85],[283],[271,188,200,285,286,214,287,187],{"trials":2732,"activeCount":95},[],{"trials":2734,"activeCount":95},[],{"trials":2736,"activeCount":95},[],{"intervention":286,"totalTrials":91,"cells":2738},{"EARLY_PHASE1":2739,"PHASE1":2741,"PHASE2":2743,"PHASE3":2749,"PHASE4":2751,"NA":2753},{"trials":2740,"activeCount":95},[],{"trials":2742,"activeCount":95},[],{"trials":2744,"activeCount":95},[2745],{"nctId":276,"briefTitle":277,"status":161,"phases":2746,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":2747,"interventions":2748},[85],[283],[271,188,200,285,286,214,287,187],{"trials":2750,"activeCount":95},[],{"trials":2752,"activeCount":95},[],{"trials":2754,"activeCount":95},[],{"intervention":287,"totalTrials":91,"cells":2756},{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2767,"PHASE4":2769,"NA":2771},{"trials":2758,"activeCount":95},[],{"trials":2760,"activeCount":95},[],{"trials":2762,"activeCount":95},[2763],{"nctId":276,"briefTitle":277,"status":161,"phases":2764,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":2765,"interventions":2766},[85],[283],[271,188,200,285,286,214,287,187],{"trials":2768,"activeCount":95},[],{"trials":2770,"activeCount":95},[],{"trials":2772,"activeCount":95},[],{"intervention":2774,"totalTrials":91,"cells":2775},"CPX-1 (Irinotecan HCl:Floxuridine) Liposome",{"EARLY_PHASE1":2776,"PHASE1":2778,"PHASE2":2780,"PHASE3":2790,"PHASE4":2792,"NA":2794},{"trials":2777,"activeCount":95},[],{"trials":2779,"activeCount":95},[],{"trials":2781,"activeCount":95},[2782],{"nctId":2783,"briefTitle":2784,"status":161,"phases":2785,"primaryCompletion":1489,"completion":1489,"start":1812,"enrollment":2786,"conditions":2787,"interventions":2789},"NCT00361842","Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer",[85],65,[2788],"Colorectal Neoplasms",[2774],{"trials":2791,"activeCount":95},[],{"trials":2793,"activeCount":95},[],{"trials":2795,"activeCount":95},[],{"intervention":326,"totalTrials":91,"cells":2797},{"EARLY_PHASE1":2798,"PHASE1":2800,"PHASE2":2802,"PHASE3":2808,"PHASE4":2810,"NA":2812},{"trials":2799,"activeCount":95},[],{"trials":2801,"activeCount":95},[],{"trials":2803,"activeCount":95},[2804],{"nctId":315,"briefTitle":316,"status":317,"phases":2805,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":2806,"interventions":2807},[85],[324],[326,187,327],{"trials":2809,"activeCount":95},[],{"trials":2811,"activeCount":95},[],{"trials":2813,"activeCount":95},[],{"intervention":2815,"totalTrials":91,"cells":2816},"pegcrisantaspase",{"EARLY_PHASE1":2817,"PHASE1":2819,"PHASE2":2821,"PHASE3":2830,"PHASE4":2832,"NA":2834},{"trials":2818,"activeCount":95},[],{"trials":2820,"activeCount":95},[],{"trials":2822,"activeCount":95},[2823],{"nctId":2824,"briefTitle":2825,"status":317,"phases":2826,"primaryCompletion":1944,"completion":462,"start":1217,"enrollment":256,"conditions":2827,"interventions":2829},"NCT02257684","A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) \u002FLymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)",[85],[31,2828],"Lymphoblastic Lymphoma",[2815],{"trials":2831,"activeCount":95},[],{"trials":2833,"activeCount":95},[],{"trials":2835,"activeCount":95},[],{"intervention":2837,"totalTrials":91,"cells":2838},"JZP150",{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2843,"PHASE3":2855,"PHASE4":2857,"NA":2859},{"trials":2840,"activeCount":95},[],{"trials":2842,"activeCount":95},[],{"trials":2844,"activeCount":95},[2845],{"nctId":2846,"briefTitle":2847,"status":161,"phases":2848,"primaryCompletion":2849,"completion":2849,"start":2850,"enrollment":2851,"conditions":2852,"interventions":2854},"NCT05178316","A Study of JZP150 in Adults With Posttraumatic Stress Disorder",[85],"2023-12-05","2021-12-29",282,[2853],"Post Traumatic Stress Disorder",[2837],{"trials":2856,"activeCount":95},[],{"trials":2858,"activeCount":95},[],{"trials":2860,"activeCount":95},[],{"intervention":1959,"totalTrials":91,"cells":2862},{"EARLY_PHASE1":2863,"PHASE1":2865,"PHASE2":2867,"PHASE3":2873,"PHASE4":2875,"NA":2877},{"trials":2864,"activeCount":95},[],{"trials":2866,"activeCount":95},[],{"trials":2868,"activeCount":95},[2869],{"nctId":1951,"briefTitle":1952,"status":161,"phases":2870,"primaryCompletion":1954,"completion":1954,"start":1955,"enrollment":1956,"conditions":2871,"interventions":2872},[85],[25],[1934,1959,1960],{"trials":2874,"activeCount":95},[],{"trials":2876,"activeCount":95},[],{"trials":2878,"activeCount":95},[],{"intervention":2880,"totalTrials":91,"cells":2881},"JZP541",{"EARLY_PHASE1":2882,"PHASE1":2884,"PHASE2":2886,"PHASE3":2898,"PHASE4":2900,"NA":2902},{"trials":2883,"activeCount":95},[],{"trials":2885,"activeCount":95},[],{"trials":2887,"activeCount":95},[2888],{"nctId":2889,"briefTitle":2890,"status":1155,"phases":2891,"primaryCompletion":2892,"completion":2892,"start":2893,"enrollment":95,"conditions":2894,"interventions":2897},"NCT05733390","A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder",[85],"2023-11-09","2023-06-30",[2895,1044,2896],"Irritability Associated With Autism Spectrum Disorder","ASD",[2880],{"trials":2899,"activeCount":95},[],{"trials":2901,"activeCount":95},[],{"trials":2903,"activeCount":95},[],{"intervention":2664,"totalTrials":91,"cells":2905},{"EARLY_PHASE1":2906,"PHASE1":2908,"PHASE2":2910,"PHASE3":2916,"PHASE4":2918,"NA":2920},{"trials":2907,"activeCount":95},[],{"trials":2909,"activeCount":95},[],{"trials":2911,"activeCount":95},[2912],{"nctId":2656,"briefTitle":2657,"status":161,"phases":2913,"primaryCompletion":2659,"completion":2633,"start":2660,"enrollment":2661,"conditions":2914,"interventions":2915},[85],[25],[2354,1960,2664],{"trials":2917,"activeCount":95},[],{"trials":2919,"activeCount":95},[],{"trials":2921,"activeCount":95},[],{"intervention":2923,"totalTrials":91,"cells":2924},"Dexamethasone",{"EARLY_PHASE1":2925,"PHASE1":2927,"PHASE2":2929,"PHASE3":2943,"PHASE4":2945,"NA":2947},{"trials":2926,"activeCount":95},[],{"trials":2928,"activeCount":95},[],{"trials":2930,"activeCount":95},[2931],{"nctId":2932,"briefTitle":2933,"status":317,"phases":2934,"primaryCompletion":2935,"completion":2936,"start":2937,"enrollment":2938,"conditions":2939,"interventions":2941},"NCT02863991","Oral ONC201 in Relapsed\u002FRefractory Multiple Myeloma",[84,85],"2019-09-17","2019-12-16","2017-04-19",17,[2940],"Multiple Myeloma",[2942,2923],"ONC201",{"trials":2944,"activeCount":95},[],{"trials":2946,"activeCount":95},[],{"trials":2948,"activeCount":95},[],{"intervention":2950,"totalTrials":91,"cells":2951},"Suvecaltamide",{"EARLY_PHASE1":2952,"PHASE1":2954,"PHASE2":2956,"PHASE3":2968,"PHASE4":2970,"NA":2972},{"trials":2953,"activeCount":95},[],{"trials":2955,"activeCount":95},[],{"trials":2957,"activeCount":95},[2958],{"nctId":2959,"briefTitle":2960,"status":161,"phases":2961,"primaryCompletion":2962,"completion":2963,"start":2964,"enrollment":2965,"conditions":2966,"interventions":2967},"NCT05642442","A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease",[85],"2024-10-23","2024-11-11","2022-12-01",169,[1568,2478],[2950],{"trials":2969,"activeCount":95},[],{"trials":2971,"activeCount":95},[],{"trials":2973,"activeCount":95},[],{"intervention":2520,"totalTrials":91,"cells":2975},{"EARLY_PHASE1":2976,"PHASE1":2978,"PHASE2":2980,"PHASE3":2986,"PHASE4":2988,"NA":2990},{"trials":2977,"activeCount":95},[],{"trials":2979,"activeCount":95},[],{"trials":2981,"activeCount":95},[2982],{"nctId":2511,"briefTitle":2512,"status":317,"phases":2983,"primaryCompletion":2514,"completion":2515,"start":2516,"enrollment":973,"conditions":2984,"interventions":2985},[85],[2518],[2520,2495],{"trials":2987,"activeCount":95},[],{"trials":2989,"activeCount":95},[],{"trials":2991,"activeCount":95},[],{"intervention":2993,"totalTrials":91,"cells":2994},"Clonazepam",{"EARLY_PHASE1":2995,"PHASE1":2997,"PHASE2":2999,"PHASE3":3008,"PHASE4":3010,"NA":3012},{"trials":2996,"activeCount":95},[],{"trials":2998,"activeCount":95},[],{"trials":3000,"activeCount":95},[3001],{"nctId":3002,"briefTitle":3003,"status":161,"phases":3004,"primaryCompletion":1489,"completion":1917,"start":1831,"enrollment":3005,"conditions":3006,"interventions":3007},"NCT00594945","Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures",[85],45,[18],[2993],{"trials":3009,"activeCount":95},[],{"trials":3011,"activeCount":95},[],{"trials":3013,"activeCount":95},[],{"intervention":170,"totalTrials":91,"cells":3015},{"EARLY_PHASE1":3016,"PHASE1":3018,"PHASE2":3020,"PHASE3":3026,"PHASE4":3028,"NA":3030},{"trials":3017,"activeCount":95},[],{"trials":3019,"activeCount":95},[],{"trials":3021,"activeCount":95},[3022],{"nctId":159,"briefTitle":160,"status":161,"phases":3023,"primaryCompletion":163,"completion":164,"start":165,"enrollment":166,"conditions":3024,"interventions":3025},[84,85],[168],[53,170],{"trials":3027,"activeCount":95},[],{"trials":3029,"activeCount":95},[],{"trials":3031,"activeCount":95},[],{"intervention":3033,"totalTrials":91,"cells":3034},"JZP385",{"EARLY_PHASE1":3035,"PHASE1":3037,"PHASE2":3039,"PHASE3":3050,"PHASE4":3052,"NA":3054},{"trials":3036,"activeCount":95},[],{"trials":3038,"activeCount":95},[],{"trials":3040,"activeCount":95},[3041],{"nctId":3042,"briefTitle":3043,"status":161,"phases":3044,"primaryCompletion":3045,"completion":3045,"start":3046,"enrollment":3047,"conditions":3048,"interventions":3049},"NCT05122650","A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)",[85],"2024-05-30","2021-12-06",420,[2109],[3033],{"trials":3051,"activeCount":95},[],{"trials":3053,"activeCount":95},[],{"trials":3055,"activeCount":95},[],{"intervention":3057,"totalTrials":91,"cells":3058},"Erwinaze®",{"EARLY_PHASE1":3059,"PHASE1":3061,"PHASE2":3063,"PHASE3":3072,"PHASE4":3074,"NA":3076},{"trials":3060,"activeCount":95},[],{"trials":3062,"activeCount":95},[],{"trials":3064,"activeCount":95},[3065],{"nctId":3066,"briefTitle":3067,"status":1155,"phases":3068,"primaryCompletion":320,"start":1195,"enrollment":95,"conditions":3069,"interventions":3071},"NCT02150928","An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)\u002FErwinase® (Crisantaspase)",[85],[3070],"Acute Lymphoblastic Leukemia (ALL)\u002FLymphoblastic Lymphoma (LBL)",[3057],{"trials":3073,"activeCount":95},[],{"trials":3075,"activeCount":95},[],{"trials":3077,"activeCount":95},[],{"intervention":2396,"totalTrials":91,"cells":3079},{"EARLY_PHASE1":3080,"PHASE1":3082,"PHASE2":3084,"PHASE3":3090,"PHASE4":3092,"NA":3094},{"trials":3081,"activeCount":95},[],{"trials":3083,"activeCount":95},[],{"trials":3085,"activeCount":95},[3086],{"nctId":2386,"briefTitle":2387,"status":161,"phases":3087,"primaryCompletion":2389,"completion":2390,"start":2391,"enrollment":2392,"conditions":3088,"interventions":3089},[85],[2394],[271,2396,2397],{"trials":3091,"activeCount":95},[],{"trials":3093,"activeCount":95},[],{"trials":3095,"activeCount":95},[],{"intervention":2397,"totalTrials":91,"cells":3097},{"EARLY_PHASE1":3098,"PHASE1":3100,"PHASE2":3102,"PHASE3":3108,"PHASE4":3110,"NA":3112},{"trials":3099,"activeCount":95},[],{"trials":3101,"activeCount":95},[],{"trials":3103,"activeCount":95},[3104],{"nctId":2386,"briefTitle":2387,"status":161,"phases":3105,"primaryCompletion":2389,"completion":2390,"start":2391,"enrollment":2392,"conditions":3106,"interventions":3107},[85],[2394],[271,2396,2397],{"trials":3109,"activeCount":95},[],{"trials":3111,"activeCount":95},[],{"trials":3113,"activeCount":95},[],{"intervention":1866,"totalTrials":91,"cells":3115},{"EARLY_PHASE1":3116,"PHASE1":3118,"PHASE2":3120,"PHASE3":3126,"PHASE4":3128,"NA":3130},{"trials":3117,"activeCount":95},[],{"trials":3119,"activeCount":95},[],{"trials":3121,"activeCount":95},[3122],{"nctId":1859,"briefTitle":1860,"status":161,"phases":3123,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":1556,"conditions":3124,"interventions":3125},[85],[18,112],[1866,1867,1841],{"trials":3127,"activeCount":95},[],{"trials":3129,"activeCount":95},[],{"trials":3131,"activeCount":95},[],{"intervention":1867,"totalTrials":91,"cells":3133},{"EARLY_PHASE1":3134,"PHASE1":3136,"PHASE2":3138,"PHASE3":3144,"PHASE4":3146,"NA":3148},{"trials":3135,"activeCount":95},[],{"trials":3137,"activeCount":95},[],{"trials":3139,"activeCount":95},[3140],{"nctId":1859,"briefTitle":1860,"status":161,"phases":3141,"primaryCompletion":1862,"completion":1862,"start":1863,"enrollment":1556,"conditions":3142,"interventions":3143},[85],[18,112],[1866,1867,1841],{"trials":3145,"activeCount":95},[],{"trials":3147,"activeCount":95},[],{"trials":3149,"activeCount":95},[],{"intervention":3151,"totalTrials":216,"cells":3152},"JZP441",{"EARLY_PHASE1":3153,"PHASE1":3155,"PHASE2":3182,"PHASE3":3184,"PHASE4":3186,"NA":3188},{"trials":3154,"activeCount":95},[],{"trials":3156,"activeCount":95},[3157,3165,3174],{"nctId":3158,"briefTitle":3159,"status":317,"phases":3160,"primaryCompletion":3161,"completion":3161,"start":3162,"enrollment":29,"conditions":3163,"interventions":3164},"NCT06961266","A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1",[84],"2026-01-29","2025-05-13",[15],[3151],{"nctId":3166,"briefTitle":3167,"status":161,"phases":3168,"primaryCompletion":3169,"completion":3169,"start":3170,"enrollment":3171,"conditions":3172,"interventions":3173},"NCT05651152","A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants",[84],"2023-11-15","2022-11-28",105,[935],[3151],{"nctId":3175,"briefTitle":3176,"status":161,"phases":3177,"primaryCompletion":3178,"completion":3178,"start":3179,"enrollment":1575,"conditions":3180,"interventions":3181},"NCT05720494","A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants",[84],"2023-09-29","2023-01-26",[935],[3151],{"trials":3183,"activeCount":95},[],{"trials":3185,"activeCount":95},[],{"trials":3187,"activeCount":95},[],{"trials":3189,"activeCount":95},[],{"intervention":3191,"totalTrials":171,"cells":3192},"Venetoclax",{"EARLY_PHASE1":3193,"PHASE1":3195,"PHASE2":3218,"PHASE3":3220,"PHASE4":3222,"NA":3224},{"trials":3194,"activeCount":95},[],{"trials":3196,"activeCount":95},[3197,3206],{"nctId":3198,"briefTitle":3199,"status":161,"phases":3200,"primaryCompletion":3201,"completion":3202,"start":3203,"enrollment":1023,"conditions":3204,"interventions":3205},"NCT04038437","A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML",[84],"2022-04-26","2022-09-24","2019-10-15",[25],[2354,3191],{"nctId":3207,"briefTitle":3208,"status":161,"phases":3209,"primaryCompletion":3210,"completion":3211,"start":3212,"enrollment":3213,"conditions":3214,"interventions":3215},"NCT04075747","A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia",[84],"2022-02-07","2023-09-12","2019-12-02",57,[25],[2354,3191,3216,3217],"Midostaurin","Enasidenib",{"trials":3219,"activeCount":95},[],{"trials":3221,"activeCount":95},[],{"trials":3223,"activeCount":95},[],{"trials":3225,"activeCount":95},[],{"intervention":3227,"totalTrials":91,"cells":3228},"Sativex spray and oral moxifloxacin placebo",{"EARLY_PHASE1":3229,"PHASE1":3231,"PHASE2":3241,"PHASE3":3243,"PHASE4":3245,"NA":3247},{"trials":3230,"activeCount":95},[],{"trials":3232,"activeCount":95},[3233],{"nctId":3234,"briefTitle":3235,"status":161,"phases":3236,"primaryCompletion":1175,"completion":1175,"start":1831,"enrollment":3237,"conditions":3238,"interventions":3240},"NCT01322139","Sativex Thorough QT\u002FQTc Study",[84],258,[3239],"Effects of Sativex on ECG",[3227,3227],{"trials":3242,"activeCount":95},[],{"trials":3244,"activeCount":95},[],{"trials":3246,"activeCount":95},[],{"trials":3248,"activeCount":95},[],{"intervention":1181,"totalTrials":91,"cells":3250},{"EARLY_PHASE1":3251,"PHASE1":3253,"PHASE2":3259,"PHASE3":3261,"PHASE4":3263,"NA":3265},{"trials":3252,"activeCount":95},[],{"trials":3254,"activeCount":95},[3255],{"nctId":1172,"briefTitle":1173,"status":161,"phases":3256,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":3257,"interventions":3258},[84],[1179],[1165,1165,1165,1181,1181],{"trials":3260,"activeCount":95},[],{"trials":3262,"activeCount":95},[],{"trials":3264,"activeCount":95},[],{"trials":3266,"activeCount":95},[],{"intervention":3268,"totalTrials":91,"cells":3269},"mPEG-r-crisantaspase",{"EARLY_PHASE1":3270,"PHASE1":3272,"PHASE2":3282,"PHASE3":3284,"PHASE4":3286,"NA":3288},{"trials":3271,"activeCount":95},[],{"trials":3273,"activeCount":95},[3274],{"nctId":3275,"briefTitle":3276,"status":161,"phases":3277,"primaryCompletion":1944,"completion":1944,"start":3278,"enrollment":1238,"conditions":3279,"interventions":3281},"NCT01551524","Phase I Study of mPEG-R-Crisantaspase Given IV",[84],"2012-03",[3280],"Hematologic Malignancies",[3268],{"trials":3283,"activeCount":95},[],{"trials":3285,"activeCount":95},[],{"trials":3287,"activeCount":95},[],{"trials":3289,"activeCount":95},[],{"intervention":3291,"totalTrials":91,"cells":3292},"JZP341",{"EARLY_PHASE1":3293,"PHASE1":3295,"PHASE2":3305,"PHASE3":3307,"PHASE4":3309,"NA":3311},{"trials":3294,"activeCount":95},[],{"trials":3296,"activeCount":95},[3297],{"nctId":3298,"briefTitle":3299,"status":317,"phases":3300,"primaryCompletion":3301,"completion":3301,"start":3302,"enrollment":1945,"conditions":3303,"interventions":3304},"NCT05631327","A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors",[84],"2024-04-24","2022-12-19",[380,381],[3291],{"trials":3306,"activeCount":95},[],{"trials":3308,"activeCount":95},[],{"trials":3310,"activeCount":95},[],{"trials":3312,"activeCount":95},[],{"intervention":3314,"totalTrials":91,"cells":3315},"ODSH at 0.125 mg\u002Fkg\u002Fh",{"EARLY_PHASE1":3316,"PHASE1":3318,"PHASE2":3330,"PHASE3":3332,"PHASE4":3334,"NA":3336},{"trials":3317,"activeCount":95},[],{"trials":3319,"activeCount":95},[3320],{"nctId":3321,"briefTitle":3322,"status":317,"phases":3323,"primaryCompletion":3324,"completion":3324,"start":2117,"enrollment":12,"conditions":3325,"interventions":3327},"NCT01161641","Pilot\u002FPh I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery",[84],"2012-02",[3326],"Protein Losing Enteropathy",[3314,3328,3329],"ODSH at 0.375 mg\u002Fkg\u002Fh","ODSH at 0.250 mg\u002Fkg\u002Fh",{"trials":3331,"activeCount":95},[],{"trials":3333,"activeCount":95},[],{"trials":3335,"activeCount":95},[],{"trials":3337,"activeCount":95},[],{"intervention":3328,"totalTrials":91,"cells":3339},{"EARLY_PHASE1":3340,"PHASE1":3342,"PHASE2":3348,"PHASE3":3350,"PHASE4":3352,"NA":3354},{"trials":3341,"activeCount":95},[],{"trials":3343,"activeCount":95},[3344],{"nctId":3321,"briefTitle":3322,"status":317,"phases":3345,"primaryCompletion":3324,"completion":3324,"start":2117,"enrollment":12,"conditions":3346,"interventions":3347},[84],[3326],[3314,3328,3329],{"trials":3349,"activeCount":95},[],{"trials":3351,"activeCount":95},[],{"trials":3353,"activeCount":95},[],{"trials":3355,"activeCount":95},[],{"intervention":3329,"totalTrials":91,"cells":3357},{"EARLY_PHASE1":3358,"PHASE1":3360,"PHASE2":3366,"PHASE3":3368,"PHASE4":3370,"NA":3372},{"trials":3359,"activeCount":95},[],{"trials":3361,"activeCount":95},[3362],{"nctId":3321,"briefTitle":3322,"status":317,"phases":3363,"primaryCompletion":3324,"completion":3324,"start":2117,"enrollment":12,"conditions":3364,"interventions":3365},[84],[3326],[3314,3328,3329],{"trials":3367,"activeCount":95},[],{"trials":3369,"activeCount":95},[],{"trials":3371,"activeCount":95},[],{"trials":3373,"activeCount":95},[],{"intervention":3375,"totalTrials":91,"cells":3376},"CMX157",{"EARLY_PHASE1":3377,"PHASE1":3379,"PHASE2":3389,"PHASE3":3391,"PHASE4":3393,"NA":3395},{"trials":3378,"activeCount":95},[],{"trials":3380,"activeCount":95},[3381],{"nctId":3382,"briefTitle":3383,"status":161,"phases":3384,"primaryCompletion":3385,"completion":3385,"start":2659,"enrollment":1238,"conditions":3386,"interventions":3387},"NCT01080820","A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers",[84],"2010-12",[1492],[3375,3388],"Viread",{"trials":3390,"activeCount":95},[],{"trials":3392,"activeCount":95},[],{"trials":3394,"activeCount":95},[],{"trials":3396,"activeCount":95},[],{"intervention":3388,"totalTrials":91,"cells":3398},{"EARLY_PHASE1":3399,"PHASE1":3401,"PHASE2":3407,"PHASE3":3409,"PHASE4":3411,"NA":3413},{"trials":3400,"activeCount":95},[],{"trials":3402,"activeCount":95},[3403],{"nctId":3382,"briefTitle":3383,"status":161,"phases":3404,"primaryCompletion":3385,"completion":3385,"start":2659,"enrollment":1238,"conditions":3405,"interventions":3406},[84],[1492],[3375,3388],{"trials":3408,"activeCount":95},[],{"trials":3410,"activeCount":95},[],{"trials":3412,"activeCount":95},[],{"trials":3414,"activeCount":95},[],{"intervention":3216,"totalTrials":91,"cells":3416},{"EARLY_PHASE1":3417,"PHASE1":3419,"PHASE2":3425,"PHASE3":3427,"PHASE4":3429,"NA":3431},{"trials":3418,"activeCount":95},[],{"trials":3420,"activeCount":95},[3421],{"nctId":3207,"briefTitle":3208,"status":161,"phases":3422,"primaryCompletion":3210,"completion":3211,"start":3212,"enrollment":3213,"conditions":3423,"interventions":3424},[84],[25],[2354,3191,3216,3217],{"trials":3426,"activeCount":95},[],{"trials":3428,"activeCount":95},[],{"trials":3430,"activeCount":95},[],{"trials":3432,"activeCount":95},[],{"intervention":3217,"totalTrials":91,"cells":3434},{"EARLY_PHASE1":3435,"PHASE1":3437,"PHASE2":3443,"PHASE3":3445,"PHASE4":3447,"NA":3449},{"trials":3436,"activeCount":95},[],{"trials":3438,"activeCount":95},[3439],{"nctId":3207,"briefTitle":3208,"status":161,"phases":3440,"primaryCompletion":3210,"completion":3211,"start":3212,"enrollment":3213,"conditions":3441,"interventions":3442},[84],[25],[2354,3191,3216,3217],{"trials":3444,"activeCount":95},[],{"trials":3446,"activeCount":95},[],{"trials":3448,"activeCount":95},[],{"trials":3450,"activeCount":95},[],{"intervention":3452,"totalTrials":91,"cells":3453},"Sativex® and fluconazole concomitantly",{"EARLY_PHASE1":3454,"PHASE1":3456,"PHASE2":3466,"PHASE3":3468,"PHASE4":3470,"NA":3472},{"trials":3455,"activeCount":95},[],{"trials":3457,"activeCount":95},[3458],{"nctId":3459,"briefTitle":3460,"status":161,"phases":3461,"primaryCompletion":1944,"completion":1944,"start":3462,"enrollment":16,"conditions":3463,"interventions":3465},"NCT02325011","An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.",[84],"2014-11",[3464],"Healthy Subjects",[2306,3452],{"trials":3467,"activeCount":95},[],{"trials":3469,"activeCount":95},[],{"trials":3471,"activeCount":95},[],{"trials":3473,"activeCount":95},[],{"intervention":272,"totalTrials":91,"cells":3475},{"EARLY_PHASE1":3476,"PHASE1":3478,"PHASE2":3484,"PHASE3":3486,"PHASE4":3488,"NA":3490},{"trials":3477,"activeCount":95},[],{"trials":3479,"activeCount":95},[3480],{"nctId":263,"briefTitle":264,"status":161,"phases":3481,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":3482,"interventions":3483},[84],[168],[271,136,188,186,272,272],{"trials":3485,"activeCount":95},[],{"trials":3487,"activeCount":95},[],{"trials":3489,"activeCount":95},[],{"trials":3491,"activeCount":95},[],{"intervention":3493,"totalTrials":91,"cells":3494},"CPX-351 (Cytarabine:Daunorubicin) Liposome",{"EARLY_PHASE1":3495,"PHASE1":3497,"PHASE2":3507,"PHASE3":3509,"PHASE4":3511,"NA":3513},{"trials":3496,"activeCount":95},[],{"trials":3498,"activeCount":95},[3499],{"nctId":3500,"briefTitle":3501,"status":161,"phases":3502,"primaryCompletion":1489,"completion":3503,"start":1226,"enrollment":1726,"conditions":3504,"interventions":3506},"NCT00389428","Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.",[84],"2009-12",[3505],"Hematologic Neoplasms",[3493],{"trials":3508,"activeCount":95},[],{"trials":3510,"activeCount":95},[],{"trials":3512,"activeCount":95},[],{"trials":3514,"activeCount":95},[],{"intervention":3516,"totalTrials":91,"cells":3517},"Sativex and rifampicin",{"EARLY_PHASE1":3518,"PHASE1":3520,"PHASE2":3534,"PHASE3":3536,"PHASE4":3538,"NA":3540},{"trials":3519,"activeCount":95},[],{"trials":3521,"activeCount":95},[3522],{"nctId":3523,"briefTitle":3524,"status":161,"phases":3525,"primaryCompletion":3526,"completion":3526,"start":1176,"enrollment":1238,"conditions":3527,"interventions":3531},"NCT01323465","Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex",[84],"2008-03",[3528,3529,3530],"Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4","Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4","Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor",[3516,3516,3532,3532,3533,3533],"Sativex and ketoconazole","Sativex and omeprazole",{"trials":3535,"activeCount":95},[],{"trials":3537,"activeCount":95},[],{"trials":3539,"activeCount":95},[],{"trials":3541,"activeCount":95},[],{"intervention":3532,"totalTrials":91,"cells":3543},{"EARLY_PHASE1":3544,"PHASE1":3546,"PHASE2":3552,"PHASE3":3554,"PHASE4":3556,"NA":3558},{"trials":3545,"activeCount":95},[],{"trials":3547,"activeCount":95},[3548],{"nctId":3523,"briefTitle":3524,"status":161,"phases":3549,"primaryCompletion":3526,"completion":3526,"start":1176,"enrollment":1238,"conditions":3550,"interventions":3551},[84],[3528,3529,3530],[3516,3516,3532,3532,3533,3533],{"trials":3553,"activeCount":95},[],{"trials":3555,"activeCount":95},[],{"trials":3557,"activeCount":95},[],{"trials":3559,"activeCount":95},[],{"intervention":3533,"totalTrials":91,"cells":3561},{"EARLY_PHASE1":3562,"PHASE1":3564,"PHASE2":3570,"PHASE3":3572,"PHASE4":3574,"NA":3576},{"trials":3563,"activeCount":95},[],{"trials":3565,"activeCount":95},[3566],{"nctId":3523,"briefTitle":3524,"status":161,"phases":3567,"primaryCompletion":3526,"completion":3526,"start":1176,"enrollment":1238,"conditions":3568,"interventions":3569},[84],[3528,3529,3530],[3516,3516,3532,3532,3533,3533],{"trials":3571,"activeCount":95},[],{"trials":3573,"activeCount":95},[],{"trials":3575,"activeCount":95},[],{"trials":3577,"activeCount":95},[],{"intervention":2079,"totalTrials":23,"cells":3579},{"EARLY_PHASE1":3580,"PHASE1":3582,"PHASE2":3584,"PHASE3":3630,"PHASE4":3664,"NA":3666},{"trials":3581,"activeCount":95},[],{"trials":3583,"activeCount":95},[],{"trials":3585,"activeCount":95},[3586,3590,3598,3605,3612,3621],{"nctId":2599,"briefTitle":2600,"status":1155,"phases":3587,"primaryCompletion":2602,"completion":2602,"start":2603,"enrollment":95,"conditions":3588,"interventions":3589},[85],[2605],[2079,1792],{"nctId":3591,"briefTitle":3592,"status":161,"phases":3593,"primaryCompletion":2552,"completion":2552,"start":3594,"enrollment":1147,"conditions":3595,"interventions":3597},"NCT00793598","CMX001 in Post-transplant Patients With BK Virus Viruria",[84,85],"2009-11",[3596],"Viruria",[2079],{"nctId":3599,"briefTitle":3600,"status":317,"phases":3601,"primaryCompletion":2602,"completion":2602,"start":3602,"enrollment":1147,"conditions":3603,"interventions":3604},"NCT03339401","The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation",[85],"2017-12-22",[2605],[2079],{"nctId":3606,"briefTitle":3607,"status":161,"phases":3608,"primaryCompletion":1298,"completion":1298,"start":2515,"enrollment":1593,"conditions":3609,"interventions":3611},"NCT00942305","Study of CMX001 to Prevent\u002FControl Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients",[85],[3610],"Cytomegalovirus Infection",[2079],{"nctId":3613,"briefTitle":3614,"status":161,"phases":3615,"primaryCompletion":3616,"completion":3616,"start":3617,"enrollment":166,"conditions":3618,"interventions":3620},"NCT01241344","Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease",[85],"2013-06","2010-11",[3619],"Adenovirus Disease",[2079],{"nctId":3622,"briefTitle":3623,"status":1155,"phases":3624,"primaryCompletion":2443,"completion":3625,"start":3626,"enrollment":95,"conditions":3627,"interventions":3629},"NCT04268966","An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola",[85],"2015-12","2014-10",[3628],"Ebola Virus Disease",[2079],{"trials":3631,"activeCount":95},[3632,3640,3644,3648,3656],{"nctId":3633,"briefTitle":3634,"status":161,"phases":3635,"primaryCompletion":3625,"completion":462,"start":2415,"enrollment":3636,"conditions":3637,"interventions":3639},"NCT01769170","A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients",[86],452,[3638],"CMV",[2079],{"nctId":2071,"briefTitle":2072,"status":317,"phases":3641,"primaryCompletion":2074,"completion":2074,"start":2075,"enrollment":12,"conditions":3642,"interventions":3643},[86],[2077],[2079,2060],{"nctId":2081,"briefTitle":2082,"status":317,"phases":3645,"primaryCompletion":2084,"completion":2085,"start":2075,"enrollment":29,"conditions":3646,"interventions":3647},[86],[2077,2087],[2079,2060],{"nctId":3649,"briefTitle":3650,"status":161,"phases":3651,"primaryCompletion":1208,"completion":1955,"start":3652,"enrollment":1372,"conditions":3653,"interventions":3655},"NCT02087306","Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection",[86],"2014-03",[3654],"Adenovirus Infection",[2079],{"nctId":3657,"briefTitle":3658,"status":161,"phases":3659,"primaryCompletion":319,"completion":319,"start":3385,"enrollment":3660,"conditions":3661,"interventions":3663},"NCT01143181","Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses",[86],210,[3662],"Double-stranded DNA Virus",[2079],{"trials":3665,"activeCount":95},[],{"trials":3667,"activeCount":95},[3668,3674],{"nctId":3669,"briefTitle":3670,"status":224,"phases":3671,"conditions":3672,"interventions":3673},"NCT02596997","Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease",[],[2605],[2079],{"nctId":3675,"briefTitle":3676,"status":317,"phases":3677,"primaryCompletion":1208,"completion":1284,"start":1944,"enrollment":867,"conditions":3678,"interventions":3679},"NCT02420080","A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304",[],[2605],[2079],{"intervention":2354,"totalTrials":3681,"cells":3682},11,{"EARLY_PHASE1":3683,"PHASE1":3685,"PHASE2":3706,"PHASE3":3734,"PHASE4":3740,"NA":3742},{"trials":3684,"activeCount":95},[],{"trials":3686,"activeCount":95},[3687,3691,3695],{"nctId":3198,"briefTitle":3199,"status":161,"phases":3688,"primaryCompletion":3201,"completion":3202,"start":3203,"enrollment":1023,"conditions":3689,"interventions":3690},[84],[25],[2354,3191],{"nctId":3207,"briefTitle":3208,"status":161,"phases":3692,"primaryCompletion":3210,"completion":3211,"start":3212,"enrollment":3213,"conditions":3693,"interventions":3694},[84],[25],[2354,3191,3216,3217],{"nctId":3696,"briefTitle":3697,"status":161,"phases":3698,"primaryCompletion":3699,"completion":3699,"start":3700,"enrollment":1081,"conditions":3701,"interventions":3705},"NCT03555955","A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351",[84],"2021-05-26","2018-11-20",[3702,25,3703,31,3704],"Hematologic Malignancy","Acute Lymphocytic Leukemia","Myelodysplastic Syndromes",[2354,2354],{"trials":3707,"activeCount":95},[3708,3712,3722,3726],{"nctId":2707,"briefTitle":2708,"status":161,"phases":3709,"primaryCompletion":2633,"completion":1298,"start":2710,"enrollment":2661,"conditions":3710,"interventions":3711},[85],[25],[2354,2698],{"nctId":3713,"briefTitle":3714,"status":1155,"phases":3715,"primaryCompletion":3716,"completion":3716,"start":2503,"enrollment":95,"conditions":3717,"interventions":3721},"NCT02269579","Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment",[85],"2017-06",[3718,3719,3720],"Acute Myeloid Leukemia (AML)","Acute Lymphoblastic Leukemia (ALL)","Myelodysplastic Syndrome (MDS)",[2354],{"nctId":2656,"briefTitle":2657,"status":161,"phases":3723,"primaryCompletion":2659,"completion":2633,"start":2660,"enrollment":2661,"conditions":3724,"interventions":3725},[85],[25],[2354,1960,2664],{"nctId":3727,"briefTitle":3728,"status":161,"phases":3729,"primaryCompletion":1585,"completion":462,"start":3730,"enrollment":3731,"conditions":3732,"interventions":3733},"NCT02238925","An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients",[85],"2014-07",26,[3718,3719,3720],[2354],{"trials":3735,"activeCount":95},[3736],{"nctId":2345,"briefTitle":2346,"status":161,"phases":3737,"primaryCompletion":2348,"completion":2348,"start":2349,"enrollment":2350,"conditions":3738,"interventions":3739},[86],[2352],[2354,2334],{"trials":3741,"activeCount":95},[],{"trials":3743,"activeCount":95},[3744,3753,3763],{"nctId":3745,"briefTitle":3746,"status":161,"phases":3747,"primaryCompletion":3748,"completion":3748,"start":3749,"enrollment":3750,"conditions":3751,"interventions":3752},"NCT05169307","CPX-351 Real-World Effectiveness and Safety Study",[],"2022-06-15","2022-01-14",147,[25],[2354],{"nctId":3754,"briefTitle":3755,"status":161,"phases":3756,"primaryCompletion":3757,"completion":1379,"start":3758,"enrollment":166,"conditions":3759,"interventions":3762},"NCT03526926","A Post-Marketing Observational Study of VYXEOS™",[],"2019-10-26","2018-10-23",[3760,3761],"Acute Myeloid Leukemia With Myelodysplasia-Related Changes","Therapy-Related Acute Myeloid Leukemia",[2354],{"nctId":3764,"briefTitle":3765,"status":716,"phases":3766,"conditions":3767,"interventions":3769},"NCT02533115","EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML",[],[3768],"Secondary AML",[2354],{"intervention":2306,"totalTrials":1112,"cells":3771},{"EARLY_PHASE1":3772,"PHASE1":3774,"PHASE2":3780,"PHASE3":3782,"PHASE4":3835,"NA":3837},{"trials":3773,"activeCount":95},[],{"trials":3775,"activeCount":95},[3776],{"nctId":3459,"briefTitle":3460,"status":161,"phases":3777,"primaryCompletion":1944,"completion":1944,"start":3462,"enrollment":16,"conditions":3778,"interventions":3779},[84],[3464],[2306,3452],{"trials":3781,"activeCount":95},[],{"trials":3783,"activeCount":95},[3784,3791,3800,3808,3816,3823,3831],{"nctId":3785,"briefTitle":3786,"status":161,"phases":3787,"primaryCompletion":2302,"completion":2302,"start":3788,"enrollment":131,"conditions":3789,"interventions":3790},"NCT00711880","A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.",[86],"2002-05",[20,1278],[2306],{"nctId":3792,"briefTitle":3793,"status":161,"phases":3794,"primaryCompletion":3795,"completion":3795,"start":1264,"enrollment":3796,"conditions":3797,"interventions":3799},"NCT00678795","A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis",[86],"2005-10",135,[3798,22],"Detrusor Overactivity",[2306],{"nctId":3801,"briefTitle":3802,"status":161,"phases":3803,"primaryCompletion":2302,"completion":2302,"start":3804,"enrollment":3805,"conditions":3806,"interventions":3807},"NCT00711646","A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.",[86],"2002-06",189,[28,22],[2306],{"nctId":3809,"briefTitle":3810,"status":161,"phases":3811,"primaryCompletion":3812,"completion":3812,"start":3813,"enrollment":2107,"conditions":3814,"interventions":3815},"NCT00713817","A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain",[86],"2007-07","2007-03",[20,1278],[2306],{"nctId":3817,"briefTitle":3818,"status":161,"phases":3819,"primaryCompletion":1236,"completion":1236,"start":1186,"enrollment":3820,"conditions":3821,"interventions":3822},"NCT00681538","A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)",[86],572,[28,22],[2306],{"nctId":3824,"briefTitle":3825,"status":161,"phases":3826,"primaryCompletion":3827,"completion":3827,"start":3795,"enrollment":3828,"conditions":3829,"interventions":3830},"NCT00713323","A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.",[86],"2007-06",380,[20,1278],[2306],{"nctId":2298,"briefTitle":2299,"status":161,"phases":3832,"primaryCompletion":2301,"completion":2302,"start":1716,"enrollment":378,"conditions":3833,"interventions":3834},[86],[2304,20,1211],[2306,2287],{"trials":3836,"activeCount":95},[],{"trials":3838,"activeCount":95},[3839],{"nctId":3840,"briefTitle":3841,"status":161,"phases":3842,"primaryCompletion":1207,"completion":1207,"start":3843,"enrollment":3844,"conditions":3845,"interventions":3847},"NCT02073474","An Observational Post-Marketing Safety Registry of Sativex®",[],"2011-02",978,[22,3846,1211,1268],"Diabetes",[2306],{"intervention":2942,"totalTrials":12,"cells":3849},{"EARLY_PHASE1":3850,"PHASE1":3852,"PHASE2":3854,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3851,"activeCount":95},[],{"trials":3853,"activeCount":95},[],{"trials":3855,"activeCount":95},[3856,3860],{"nctId":2932,"briefTitle":2933,"status":317,"phases":3857,"primaryCompletion":2935,"completion":2936,"start":2937,"enrollment":2938,"conditions":3858,"interventions":3859},[84,85],[2940],[2942,2923],{"nctId":3861,"briefTitle":3862,"status":1155,"phases":3863,"primaryCompletion":3625,"completion":1600,"start":3864,"enrollment":95,"conditions":3865,"interventions":3870},"NCT02038699","A First-in-man Phase I\u002FII Study of Oral ONC201 in Patients With Advanced Cancer",[84,85],"2014-01",[3866,3867,3868,3869],"Advanced Glioblastoma","Advanced Colorectal Cancer","Advanced Triple-negative Breast Cancer","Advanced Non-small Cell Lung Cancer",[2942],{"trials":3872,"activeCount":95},[],{"trials":3874,"activeCount":95},[],{"trials":3876,"activeCount":95},[3877,3883,3889],{"nctId":3878,"briefTitle":3879,"status":716,"phases":3880,"conditions":3881,"interventions":3882},"NCT04617002","Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and\u002For Midline Gliomas",[],[455,492],[2942],{"nctId":3884,"briefTitle":3885,"status":224,"phases":3886,"conditions":3887,"interventions":3888},"NCT05392374","Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas",[],[455],[2942],{"nctId":3890,"briefTitle":3891,"status":224,"phases":3892,"conditions":3893,"interventions":3894},"NCT03134131","Expanded Access to ONC201 for Patients With H3 K27M-mutant and\u002For Midline High Grade Gliomas",[],[455],[2942],{"intervention":3896,"totalTrials":256,"cells":3897},"CMX001",{"EARLY_PHASE1":3898,"PHASE1":3900,"PHASE2":3915,"PHASE3":3924,"PHASE4":3926,"NA":3928},{"trials":3899,"activeCount":95},[],{"trials":3901,"activeCount":95},[3902,3908],{"nctId":3903,"briefTitle":3904,"status":161,"phases":3905,"primaryCompletion":1489,"completion":1236,"start":2660,"enrollment":1575,"conditions":3906,"interventions":3907},"NCT00780182","Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers",[84],[1492],[3896],{"nctId":3909,"briefTitle":3910,"status":161,"phases":3911,"primaryCompletion":3912,"completion":3912,"start":3843,"enrollment":1187,"conditions":3913,"interventions":3914},"NCT05391724","Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects",[84],"2011-09",[1199],[3896],{"trials":3916,"activeCount":95},[3917],{"nctId":3918,"briefTitle":3919,"status":1155,"phases":3920,"primaryCompletion":1207,"completion":1207,"start":3626,"enrollment":95,"conditions":3921,"interventions":3923},"NCT02271347","An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease",[85],[3922],"Ebola Virus",[3896],{"trials":3925,"activeCount":95},[],{"trials":3927,"activeCount":95},[],{"trials":3929,"activeCount":95},[3930],{"nctId":3931,"briefTitle":3932,"status":317,"phases":3933,"primaryCompletion":2602,"completion":2602,"start":3864,"enrollment":181,"conditions":3934,"interventions":3937},"NCT02167685","The Chimerix CMX001 Registry",[],[3935,3936],"Outcomes","Survival Rates",[3896],{"intervention":3939,"totalTrials":171,"cells":3940},"asparaginase Erwinia chrysanthemi",{"EARLY_PHASE1":3941,"PHASE1":3943,"PHASE2":3945,"PHASE3":3954,"PHASE4":3956,"NA":3958},{"trials":3942,"activeCount":95},[],{"trials":3944,"activeCount":95},[],{"trials":3946,"activeCount":95},[3947],{"nctId":3948,"briefTitle":3949,"status":161,"phases":3950,"primaryCompletion":2415,"completion":1286,"start":3951,"enrollment":11,"conditions":3952,"interventions":3953},"NCT01643408","A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy",[85],"2012-11",[31,2828],[3939],{"trials":3955,"activeCount":95},[],{"trials":3957,"activeCount":95},[],{"trials":3959,"activeCount":95},[3960],{"nctId":3961,"briefTitle":3962,"status":716,"phases":3963,"conditions":3964,"interventions":3965},"NCT04943952","JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL \u002F LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase",[],[31,2828],[3966],"Asparaginase Erwinia Chrysanthemi",{"intervention":3968,"totalTrials":91,"cells":3969},"Vyxeos liposomal",{"EARLY_PHASE1":3970,"PHASE1":3972,"PHASE2":3974,"PHASE3":3976,"PHASE4":3978,"NA":3980},{"trials":3971,"activeCount":95},[],{"trials":3973,"activeCount":95},[],{"trials":3975,"activeCount":95},[],{"trials":3977,"activeCount":95},[],{"trials":3979,"activeCount":95},[],{"trials":3981,"activeCount":95},[3982],{"nctId":3983,"briefTitle":3984,"status":161,"phases":3985,"primaryCompletion":3986,"completion":3986,"start":3987,"enrollment":3988,"conditions":3989,"interventions":3990},"NCT06143839","VYxeoS Liposomal Italian Observational Study iN the Real Practice",[],"2025-10-23","2023-12-07",113,[3718,3760,3761],[3968],{"intervention":3992,"totalTrials":91,"cells":3993},"Ziconotide",{"EARLY_PHASE1":3994,"PHASE1":3996,"PHASE2":3998,"PHASE3":4000,"PHASE4":4002,"NA":4004},{"trials":3995,"activeCount":95},[],{"trials":3997,"activeCount":95},[],{"trials":3999,"activeCount":95},[],{"trials":4001,"activeCount":95},[],{"trials":4003,"activeCount":95},[],{"trials":4005,"activeCount":95},[4006],{"nctId":4007,"briefTitle":4008,"status":161,"phases":4009,"primaryCompletion":1566,"completion":1285,"start":1196,"enrollment":2626,"conditions":4010,"interventions":4012},"NCT01888120","Patient Registry of Intrathecal Ziconotide Management(PRIZM)",[],[4011],"Patients With Severe Chronic Pain",[3992],{"intervention":4014,"totalTrials":91,"cells":4015},"Zepzelca",{"EARLY_PHASE1":4016,"PHASE1":4018,"PHASE2":4020,"PHASE3":4022,"PHASE4":4024,"NA":4026},{"trials":4017,"activeCount":95},[],{"trials":4019,"activeCount":95},[],{"trials":4021,"activeCount":95},[],{"trials":4023,"activeCount":95},[],{"trials":4025,"activeCount":95},[],{"trials":4027,"activeCount":95},[4028],{"nctId":4029,"briefTitle":4030,"status":161,"phases":4031,"primaryCompletion":4032,"completion":4032,"start":4033,"enrollment":4034,"conditions":4035,"interventions":4036},"NCT04894591","To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)",[],"2025-06-04","2021-06-28",272,[413],[4014],{"intervention":4038,"totalTrials":91,"cells":4039},"Transition from Xyrem to Xywav",{"EARLY_PHASE1":4040,"PHASE1":4042,"PHASE2":4044,"PHASE3":4046,"PHASE4":4048,"NA":4050},{"trials":4041,"activeCount":95},[],{"trials":4043,"activeCount":95},[],{"trials":4045,"activeCount":95},[],{"trials":4047,"activeCount":95},[],{"trials":4049,"activeCount":95},[],{"trials":4051,"activeCount":95},[4052],{"nctId":4053,"briefTitle":4054,"status":161,"phases":4055,"primaryCompletion":4056,"completion":4056,"start":4057,"enrollment":4058,"conditions":4059,"interventions":4060},"NCT04803786","A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy",[],"2022-02-24","2021-04-09",110,[15],[4038]]